

Aging Of Antiviral CD8⁺ Memory T Cells Fosters Increased Survival, Metabolic Adaptations And Lymphoid Tissue Homing

Bennett Davenport^{1-5*}, Jens Eberlein^{1,2*}, Verena van der Heide^{4,5}, Kevin Jhun^{4,5}, Tom T. Nguyen^{1,2}, Francisco Victorino¹⁻³, Andrew Trotta⁶, Jerry Chipuk⁶, Zhengzi Yi⁷, Weijia Zhang⁷, Eric T. Clambey^{1,3}, Donald K. Scott⁴, and Dirk Homann^{1-5**}

¹*Department of Anesthesiology & ²Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO;*

³*Integrated Department of Immunology, University of Colorado Denver and National Jewish Health, Denver CO;*

⁴*Diabetes Obesity Metabolism Institute, ⁵Immunology Institute,*

⁶*Department of Oncological Sciences & ⁷Bioinformatics Laboratory Icahn School of Medicine at Mount Sinai, New York, NY*

****Correspondence:**

Dirk Homann, MD
Diabetes Obesity Metabolism & Immunology Institutes
Mount Sinai School of Medicine
One Gustave L. Levy Place - Box 1152
New York, NY 10029

ph: 212 241-1935
fax: 212 241-2485
email: dirk.homann@mssm.edu

*BD and JE contributed equally

Short Title: Homeostatic Adaptations Of Aging Antiviral CD8⁺T_M

ABSTRACT

Aging of established antiviral T cell memory fosters a series of progressive adaptations that paradoxically improve rather than compromise protective CD8⁺T cell immunity. We now provide evidence that this gradual evolution, the pace of which is contingent on the precise context of the primary response, also impinges on the molecular mechanisms that regulate CD8⁺ memory T cell (CD8⁺T_M) homeostasis. Over time, CD8⁺T_M become more resistant to apoptosis and acquire enhanced cytokine responsiveness without adjusting their homeostatic proliferation rates; concurrent metabolic adaptations promote increased CD8⁺T_M quiescence and fitness but also impart the re-acquisition of a partial effector-like metabolic profile; and a gradual redistribution of aging CD8⁺T_M from blood and nonlymphoid tissues to lymphatic organs results in CD8⁺T_M accumulations in bone marrow, splenic white pulp and particularly lymph nodes. Altogether, these data demonstrate how temporal alterations of fundamental homeostatic determinants converge to render aged CD8⁺T_M poised for greater recall responses.

ABBREVIATIONS

AT:	adoptive transfer
ATGL:	adipose triglyceride lipase
BMP:	blood and marginated pool
FA, FAO, FAS, FASN:	fatty acid, fatty acid oxidation, fatty acid synthesis, fatty acid synthase
FSC, SSC:	forward scatter, side scatter
GMFI:	geometric mean of fluorescence intensity
GP, NP:	glycoprotein, nucleoprotein
GSEA:	gene set enrichment analysis
GSH:	glutathione
I ^o , II ^o :	primary, secondary
KEGG:	Kyoto Encyclopedia of Genes and Genomes
LAL:	lysosomal acid lipase (LIPA)
LCMV:	lymphocytic choriomeningitis virus
NES:	normalized enrichment score
NLTs:	nonlymphoid tissues
O, Y:	old, young
OxPhos:	oxidative phosphorylation
p14 cells:	TCRtg CD8 ⁺ T cells specific for the LCMV-GP ₃₃₋₄₁ determinant
RP, WP:	red pulp, white pulp (spleen)
T cell subsets	
T _E :	effector T cells
T _{CM} :	central memory T cells (CD62L ^{hi})
T _{EM} :	effector memory T cells (CD62L ^{lo})
T _{EMRA} :	terminally differentiated CD45RA ⁺ effector memory T cells (human)
T _M :	memory T cells
T _{MP} :	memory-phenotype T cells (CD44 ^{hi})
T _N :	naïve T cells (CD44 ^{lo})
T _{RM} :	resident memory T cells (CD69/CD103-enriched)
TCRtg:	T cell receptor transgenic
TSLP:	Thymic stromal lymphopoietin

INTRODUCTION

The long-term preservation of antiviral T cell memory is a highly dynamic process that promotes the progressive molecular, phenotypic and functional remodeling of its principal constituents, the populations of specific CD8⁺ memory T cells (CD8⁺T_M) distributed throughout and often trafficking between various anatomic compartments. We recently demonstrated that this process can culminate, paradoxically, in the acquisition of naïve-like T cell traits, enhanced recall potential and greater protective capacities of aged CD8⁺T_M [1]. The notion that aging can improve CD8⁺T cell memory [1-5] stands in apparent contrast to much of the literature documenting numerous and often deleterious consequences of T cell aging [6-9]. A more focused review [10], however, indicates that eventual “immunosenescence” is not necessarily a fate shared by all T cell subsets and CD8⁺T_M generated earlier in life to an acute, non-persisting pathogen challenges can be maintained over time without accruing obvious functional defects [9, 11, 12]. In fact, a coexistence of age-associated alterations that either impair or improve CD8⁺T cell immunity is illustrated in aged mice that exhibit a diminished capacity for generation of primary (I^o) antiviral CD8⁺ effector T cell (CD8⁺T_E) responses yet readily support the greater secondary (II^o) expansion of old as compared to young CD8⁺T_M specific for the same viral determinants [1].

To elucidate the foundations and consequences of successful CD8⁺T_M aging in greater detail, we previously generated a set of integrated data sets that collectively trace the evolving molecular, phenotypic and functional properties of aging virus-specific CD8⁺T_M [1]. We further organized the patterns of gradual CD8⁺T_M remodeling in a conceptual framework designated the “rebound model” of progressive CD8⁺T_M “de-differentiation” that postulates an inverse relationship between the extent of I^o CD8⁺T_E differentiation and the pace with which aging CD8⁺T_M populations, over a period of ~2 years, acquire a broad spectrum of distinctive and increasingly homogenous traits. Specifically, aging of CD8⁺T_M populations modulates the expression of at least ~80 cell surface receptors/ligands, produces a more diversified functional repertoire, and eventually endows old CD8⁺T_M in a T cell-intrinsic fashion with an improved capacity for the generation of protective II^o responses [1]. In the present report, we have delineated the impact of aging on the cardinal components of CD8⁺T_M homeostasis (survival, homeostatic proliferation, metabolism, tissue residence/trafficking) and our findings demonstrate that the cumulative homeostatic adaptations converge to establish a spatio-functional foundation for improved recall responses of aged CD8⁺T_M.

RESULTS AND DISCUSSION

Temporal regulation of survival- & apoptosis-related gene and protein expression by aging CD8⁺T_M.

Challenge of mice with the natural murine pathogen lymphocytic choriomeningitis virus (LCMV) induces a potent antiviral CD8⁺T_E response that rapidly controls the infection and permits the subsequent development of specific CD8⁺T_M that are maintained for life in the absence of residual viral antigens [13, 14]. In B6 mice, the principal LCMV-specific CD8⁺T cell populations target the nucleo- and glycoprotein determinants NP₃₉₆₋₄₀₄ and GP₃₃₋₄₁; in addition, naïve TCRtg p14 cells specific for LCMV-GP₃₃₋₄₁ and transferred into congenic B6 mice can be used to construct “p14 chimeras” for facilitated interrogation of a clonotypic CD8⁺T_M population (p14 T_M). A combination of p14 chimera and B6 systems provided the experimental foundation for our comprehensive delineation of aging antiviral CD8⁺T_M properties [1], and drawing on these resources, we have now revisited the foundations of long-term CD8⁺T_M survival [15] by conducting modified gene set enrichment analyses (GSEAs) that specifically leverage the temporal aspect of our p14 T_M data sets (see Methods). Here, of 132 gene sets comprising 10,945 genes and exhibiting age-associated modulations, ~20% (26/132) were enriched and ~80% (106/132) were depleted in old p14 T_M, the latter group including the KEGG apoptosis pathway (**Fig. 1A**). Within this module, 14 genes belonged to the Bcl-2, BIRC (baculoviral IAP [inhibitors of apoptosis proteins] repeat-containing) or caspase gene families and their combined temporal regulation pointed towards reduced apoptosis susceptibility of aged p14 T_M (**Fig. 1A**).

Members of the Bcl-2 family have long been implicated in lymphocyte survival and death, and the balanced expression of anti-apoptotic Bcl-2 and pro-apoptotic BIM controls survival of naïve and, to a somewhat lesser extent, memory phenotype CD8⁺T cells (CD8⁺T_N and CD8⁺T_{MP}, respectively) [16]. Our interrogation of individual Bcl-2 family members revealed predominantly stable expression by aging p14 T_M with two notable exceptions, the modestly rising levels of *Bcl2* and *Bcl2l1* (**Fig. S1A-C**). Importantly, the transcriptional changes were accompanied by a substantial increase of Bcl-2 protein content in aging CD8⁺T_M and a slight, though significant, enhancement of BIM such that the resulting Bcl-2:BIM expression ratio steadily increased over time (**Fig. 1B/C**). Given a progressive enrichment for the CD62L^{hi} phenotype among aging antiviral CD8⁺T_M [1, 17], our findings are also in agreement with the reported elevation of both Bcl-2 and BIM in antiviral CD8⁺T_{CM} as compared to T_{EM} populations [18]. We emphasize, however, that these expression differences themselves are subject to an extended temporal modulation since the continuous rise of the Bcl-2:BIM ratios occurred in aging CD8⁺T_{CM} and T_{EM} subsets alike (**Fig. 1C**). We also note the persistence of relatively stable Bcl-x_L levels (**Fig. 1D**); a gradual increase of several BIRC family genes that may contribute to an enhanced survival advantage for aged CD8⁺T_M [19, 20] (**Fig. S1D**); and the pronounced decline of *Casp3* mRNA without evidence for caspase-3 activation [21] throughout long-term T cell memory (**Figs. 1D & S1E**). Altogether, the kinetics of gene and protein expression therefore indicate that aging CD8⁺T_M may be endowed with increasing overall fitness.

Enhanced apoptosis resistance of aging CD8⁺T_M.

When assessed directly *ex vivo*, the viability of CD8⁺T_M was not affected by age (**Fig.2A**), but an *in vitro* culture in the absence of added growth/survival factors (“withdrawal apoptosis”) documented a gradual decline of CD8⁺T_M death as a function of age (**Fig.2B**). Increased apoptosis resistance has been associated with aging and cellular senescence [22] but the CD8⁺T_M under investigation here lacked phenotypic and functional features of incapacitation [1], including the hallmark of murine T cell senescence, increased P-glycoprotein activity [23]. Nonetheless, a distinct survival advantage of “non-senescent” old CD8⁺T_{MP} was previously observed under conditions of “withdrawal apoptosis” and attributed, despite an exacerbated decline of mitochondrial membrane potentials ($\Delta\Psi_m$), to reduced production of reactive oxygen species (ROS), elevated intracellular thiol levels (largely representing the abundance of reduced glutathione/GSH), and increased expression of phase II antioxidant enzymes that combine to protect aged CD8⁺T_{MP} against oxidative stress, mitochondrial dysfunction and death [24, 25]. In our model system, aging virus-specific CD8⁺T_M also exhibited a modest decline of *ex vivo* ROS production (**Fig.2C**) and a more striking loss of $\Delta\Psi_m$ after *in vitro* culture (**Fig.2D**). Yet despite an enrichment of genes within the GSH metabolism pathway (**Fig.2E**) that may collectively provide a metabolic advantage [26] for recall responses, we observed only a marginal rise of intracellular thiol levels in aging CD8⁺T_M (**Fig.2F**), and regardless of a 1.9-fold increase of *Nfe2l2* mRNA [1] (the major TF in control of phase II enzyme regulation), no evidence for elevated induction of the respective genes could be obtained (not shown). Instead, we found a pronounced augmentation of cell surface thiol levels by aging CD8⁺T_M that was likely the result of changing microenvironments in older mice as demonstrated by their significantly increased serum thiol levels (**Fig.2G**); this conclusion is also consistent with the notion that the immediate microenvironment rather than intracellular GSH levels preferentially determines the redox status of cell surface molecules [27].

Life & death of aging CD8⁺T_M: improved survival through increased Bcl-2:BIM expression ratios.

Collectively, the above observations suggest that T cell-intrinsic mechanisms, in particular the rising Bcl-2:BIM expression ratio, may confer a survival advantage to aging CD8⁺T_M. To directly evaluate this possibility we employed a co-culture system to monitor survival of congenic old and young CD8⁺T_M in the same *in vitro* environment. Addition of the Bcl-2 inhibitor ABT-737 [28] to cultures precipitated CD8⁺T cell death in a dose-dependent fashion and, at a saturating concentration of 150nM, reduced total CD8⁺T cell survival to ~10% (**Fig.2H**). The relative survival advantage of old vs. young D^bNP₃₉₆⁺ CD8⁺T_M, however, was maintained at lower ABT-737 dosages and only disappeared at ~100nM providing direct evidence for the exquisite dependence of CD8⁺T_M survival on Bcl-2 and its role in promoting enhanced apoptosis resistance of aged CD8⁺T_M populations (**Fig.2H**). Although ABT-737 binds to Bcl-x_L and Bcl-w in addition to Bcl-2 [28], the low-level expression of corresponding mRNA species and, in the case of Bcl-x_L also protein (**Figs.S1A & 1C**), supported the notion of Bcl-2 as the major ABT-737 target in CD8⁺T_M. Further evidence for the elevated Bcl-2:BIM ratio as a determinant for enhanced survival of aged CD8⁺T_M came from a reversal of survival advantages at saturating ABT-737 concentrations (150nM, **Fig.2H**): although very few cells remained alive under conditions of complete Bcl-2 blockade, the slightly better survival of residual young CD8⁺T_M may be explained by their comparatively lower BIM expression since death of Bcl-2-deficient T cells was shown earlier to decline as a function of BIM gene dosage (*Bcl2l1*^{+/+} > *Bcl2l1*^{+/-} > *Bcl2l1*^{-/-}) [16].

In the context of an acute response, both I^0 and II^0 $CD8^+T_E$ downregulate Bcl-2 expression [29], and control of $CD8^+T_E$ subset survival is thought to switch to other factors, perhaps including the BIRC family member survivin/Birc5 [30] (**Fig.S1D**). Work with a Bcl-2 reporter mouse, however, indicates that even at the peak of a pathogen-specific immune response, $CD8^+T_E$ populations are characterized by a spread of Bcl-2 expression levels that permits the distinction of $CD8^+T_E$ subsets with differential memory potential [31]. In line with these observations, we found that II^0 $CD8^+T_E$ derived from aged $CD8^+T_M$ exhibited a slight yet significant elevation of Bcl-2 as compared to I^0 $CD8^+T_E$ or II^0 $CD8^+T_E$ generated from young $CD8^+T_M$ (**Fig.2I**). Coupled with the former cells' improved survival during the ensuing contraction phase [1], our results therefore hinted at a direct role for Bcl-2 in promoting a more effective establishment of II^0 $CD8^+T$ cell memory. Indeed, while young II^0 $CD8^+T_M$ featured reduced Bcl-2 contents compared to I^0 $CD8^+T_M$ as reported previously [29], old II^0 $CD8^+T_M$ present within the same hosts exhibited substantially higher Bcl-2 levels (**Fig.2I**). Thus, the largely Bcl-2-dependent survival advantage of old over young I^0 $CD8^+T_M$ was re-established in the course of II^0 memory formation.

Overall, the dynamic regulation of Bcl-2 re-expression in the memory phase (**Fig.1B/C**) followed a pattern similar to that of multiple other phenotypic/functional $CD8^+T_M$ properties subject to age-associated expression modulation [1]. Since the precise pace of these changes could be experimentally accelerated or delayed as a function of initial $CD8^+T_N$ precursor frequency or infection dosage [1], we surmised that Bcl-2 expression by $CD8^+T_M$ could be controlled in a comparable fashion. Here, we constructed p14 chimeras with titrated numbers of p14 T_N ($2 \times 10^2 - 2 \times 10^5$) and challenged the mice with a standard dose of LCMV (2×10^5 pfu), or generated p14 chimeras with a fixed p14 T_N number (1×10^4) and infection with graded dosages of LCMV ($2 \times 10^3 - 2 \times 10^7$ pfu). Measuring Bcl-2 expression by p14 T_M 6-7 weeks later, we found that an increase of p14 T_N input numbers enhanced, while an escalation of the virus challenge dose reduced respective Bcl-2 levels in p14 T_M (**Fig.2J**). In summary, our results demonstrate that aging $CD8^+T_M$ become more resistant to apoptosis, that their improved survival and that of their II^0 progeny is principally controlled through increased Bcl-2 expression, and that the specific conditions of $CD8^+T_E$ generation determine the pace of progressive Bcl-2 upregulation by $CD8^+T_M$.

Cytokine receptor expression, signaling & homeostatic proliferation of aging $CD8^+T_M$

In direct relation to their longevity, regulation of $CD8^+T_M$ fates under steady-state conditions also involves homeostatic proliferation, the slow and stochastic division of “resting” $CD8^+T_M$ governed by the cytokines IL-7 and IL-15 [15, 32]. In extension of our previous report [1], we now demonstrate that a progressive upregulation of the respective cytokine receptors (CD127 and CD122) by aging $CD8^+T_M$ also pertains to the PBMC compartment and to differential $CD8^+T_M$ specificities (**Fig.3A/B**) suggesting that their homeostatic proliferation rates may be adjusted accordingly. To determine if enhanced cytokine receptor expression indeed conveyed greater responsiveness, we assessed the extent of IL-7/IL-15-induced STAT5 phosphorylation in young and old p14 chimeras. Here, aged p14 T_M not only exhibited greater reactivity, but at limiting concentrations IL-7 clearly proved to be a more effective activator of STAT5 than IL-15 (**Fig.3C**). These findings extend the notion of superior IL-7 potency in the context of initial $CD8^+T_M$ formation [33] to the long-term maintenance of $CD8^+T_M$,

and complement a recent observation about enhanced IL-15 reactivity of “late” p14 T_M or T_{CM} (>8 months after infection) as compared to “early” p14 T_M/T_{CM} (d30-45) [5]. We further note that the thymic stromal lymphopoietin receptor (TSLPR) is apparently the only CD8⁺T_M-expressed cytokine receptor subject to a gradual downmodulation over time [1], a pattern that could contribute to the amplified IL-7 reactivity of aged CD8⁺T_M as it may permit enhanced complex formation of CD127 with CD132 rather than TSLPR [34].

While the above findings correlate increased CD127/CD122 expression with CD8⁺T_M reactivity to IL-7/IL-15, we also noted a certain extent of constitutive STAT5 phosphorylation among p14 T_M analyzed directly *ex vivo*, similar to the basal STAT5 phosphorylation observed in human CD8⁺T cell subsets of undefined specificity [35]. Additional control experiments confirmed this conclusion (**Fig.S2A**) but unexpectedly, the levels of constitutive STAT5 phosphorylation remained unaltered in aging antiviral CD8⁺T_M populations (**Fig.3D**). Since the level of active STAT5 appears to control homeostatic proliferation rates [36], stable pSTAT5 expression by endogenously generated CD8⁺T_M therefore suggested that their homeostatic proliferation rates, despite enhanced sensitivity to IL-7/IL-15, might not be accelerated. This prediction was reinforced by our longitudinal p14 T_M GSEAs that demonstrated a negative (though not significant) enrichment of cell cycle-associated genes and thus also argued against an accelerated CD8⁺T_M turnover (**Fig.S2B**). Indeed, as assessed by *ex vivo* Ki67 expression, homeostatic proliferation of blood-borne LCMV-specific CD8⁺T_M was unaffected by age (**Fig.3E**), a contention corroborated through the comparable *in vivo* BrdU incorporation by young and old CD8⁺T_M in various lymphatic and nonlymphoid tissues (NLTs) (**Fig.3F**). Thus, in contrast to murine CD8⁺T_{MP} of undefined specificity [37], homeostatic proliferation rates of virus-specific CD8⁺T_M were largely independent of age but remained susceptible to modulation by tissue-specific microenvironments as shown for young CD8⁺T_M [38].

Finally, it is important to note that homeostatic proliferation rates are not simply an intrinsic property of phenotypically defined CD8⁺T_M subsets. For example, the CD62L^{hi} CD8⁺T_{CM} population, previously reported to exhibit higher homeostatic proliferation rates than CD8⁺T_{EM} [17, 39], accumulates in the spleen over time [1, 17] without causing an overall acceleration of homeostatic turnover (**Fig.3E/F**). And although we confirmed the differential homeostatic proliferation rates of splenic CD8⁺T_{CM} vs. T_{EM} in young LCMV-immune mice, we found no differences in other tissues such as LNs (**Fig.3G**). The absence of a simple correlation between CD8⁺T_M subsets, rates of homeostatic proliferation, cytokine receptor (CD127/CD122) and even corresponding tissue-specific cytokine (IL7/IL15) expression levels (**Fig.S2C**) constitutes an important caveat that needs to inform further investigations into the homeostasis of CD8⁺T_M populations.

Metabolic adaptations of aging CD8⁺T_M.

Initial CD8⁺T_E differentiation and CD8⁺T_M generation are both controlled and accompanied by varied metabolic adaptations. Activation of “quiescent” naïve CD8⁺T_N engages a “metabolic switch” that endows emerging CD8⁺T_E with high rates of aerobic glycolysis and glutaminolysis to support an anabolic metabolism; the subsequent development of CD8⁺T cell memory is characterized by a gradual return to metabolic quiescence and a preferential reliance on fatty acid oxidation (FAO) and oxidative phosphorylation (OxPhos) to

meet the changing energy demands [40]. The extent to which established CD8⁺T_M populations may further adapt their metabolism over time, however, remains little explored [5]. We previously reported that aging CD8⁺T_M exhibit a subtle yet significant increase of cellular size and “granularity/complexity” (determined by forward [FSC] and side scatter [SSC] properties, respectively) [1], a process most likely controlled by mTOR activity [41, 42]. Indeed, we now find that basal mTOR protein (though not mRNA) expression by antiviral CD8⁺T_M increased with age as did message for ribosomal protein S6 (*Rps6*, a downstream target of the mTORC1 complex involved in the regulation of cell size, proliferation and glucose homeostasis) and, importantly, the degree of Rps6 protein phosphorylation (**Fig.4A/B**). Although the convergence of elevated mTORC1 activity, cell size and recall capacity of aged CD8⁺T_M [1] is consistent, these adjustments would appear to run counter to the shift towards reduced glycolysis and increased OxPhos as observed for the earlier transition from CD8⁺T_E to young T_M stage [40]. Interestingly, however, most recent work indicates that enforcement of sustained glycolysis and suppression of OxPhos does not compromise but rather may accelerate CD8⁺T_M formation [43]. Therefore, to assess the extended evolution of metabolic CD8⁺T_M profiles, we reviewed our temporal GSEAs and found that ~25% of all pathways up- or downregulated by p14 T_M over time could in fact be assigned to the broad KEGG category of “metabolism”. Here, a collective depletion of carbohydrate, energy, lipid, amino acid and glycan pathways in aging p14 T_M suggested a continued trend towards metabolic quiescence yet the gene sets comprising glycolysis, nucleotide and glutathione metabolism were simultaneously enriched (**Fig.4C** and not shown). In the absence of significant differences for the majority of these temporally regulated pathways (**Fig.4C**), the age-associated alterations of CD8⁺T_M metabolism are therefore expected to be subtle but nevertheless should be reflected in a distinct modulation of glucose and fatty acid utilization.

With regard to glucose metabolism, our transcriptional p14 T_M data indicated that within the family of facilitative glucose transporters, robust gene expression was restricted to stable *Slc2a1*/Glut1 and progressively declining *Slc2a3*/Glut3 mRNA species (**Fig.4D**). Yet while corresponding Glut3 protein expression levels mirrored the decline of *Slc2a3* mRNA, total Glut1 expression was subject to distinct translational modulations: high in CD8⁺T_E, reduced in young CD8⁺T_M but intermediate in aged CD8⁺T_M (**Fig.4E**). Importantly, a specific interrogation of surface Glut1 confirmed the enhanced expression by old vs. young CD8⁺T_M, and the differential Glut1 levels in CD8⁺T_{E/M} populations correlated precisely with their respective glucose uptake capacities (**Fig.4E**). In contrast, greater rates of glucose uptake by CD8⁺T_N than either CD8⁺T_E or young T_M, also observed in other reports [44, 45], did not correspond to enhanced Glut1 levels in our experiments (**Fig.4E**); however, neither glucose uptake nor *in vitro* survival of resting T cells is affected by Glut1-deficiency and may instead rely on related transporters such as Glut3 [46]. The notion of enhanced glucose utilization by aged as compared to young CD8⁺T_M is further supported by the pattern of CD8⁺T cell-expressed insulin receptor (*Insr*/CD220) that significantly increases with CD8⁺T_M age (**Figs.S3A & 4F**). Insulin not only regulates glucose uptake but also acts as a major growth factor that increases protein translation [47]. In fact, of the 26 gene sets demonstrating a progressive enrichment in aging p14 T_M, nearly half are captured under the general category of “genetic information processing” that includes pathways for transcription; translation; folding, sorting and degradation; as well as replication and repair (**Fig.S3B**).

If CD8⁺T_M aging fosters a trend towards increased glucose utilization, it should simultaneously decrease OxPhos and FA utilization, and our GSEAs indicate that this is the case (**Fig.4C**). To directly determine the amount of stored fat in CD8⁺T cells, we quantified neutral lipid content in CD8⁺T_N and virus-specific CD8⁺T_{E/M} populations. As expected [45] and albeit subtle, young CD8⁺T_M contained fewer neutral lipids than CD8⁺T_E but old CD8⁺T_M stored even less (**Fig.4G**). In further agreement with O'Sullivan *et al.* [45] we also noted a decreased capacity for long-chain FA (FL C₁₆) and low-density lipoprotein (LDL) uptake in young CD8⁺T_M as compared to CD8⁺T_E, a competence that, importantly, eroded even further with age (**Fig.4G**). Reduced FA uptake, however, is not *per se* an indicator for decreased FA metabolism since CD8⁺T_M fuel their bioenergetics needs in a “futile cycle” that utilizes extracellular glucose to support both increased FA synthesis (FAS) and FAO [45]. With the aim to delineate the relative contribution of FAS and FAO to CD8⁺T_M metabolism [48] specifically in the context of aging, we incubated the various CD8⁺T cell populations in the presence of titrated amounts of selected pharmacological inhibitors and assessed their respective survival. Overall, both young and old CD8⁺T_M proved more resistant to inhibition of lipogenesis or lipolysis than either CD8⁺T_E or T_N (**Figs.4H/I & S3C-E**). Yet subtle differences between young and aged CD8⁺T_M could be discerned at particular inhibitor concentrations. Here, inhibition of fatty acid synthase (FASN) by 30μM of the compound C75 compromised survival of young vs. old CD8⁺T_M to a greater extent suggesting that aged CD8⁺T_M are somewhat less reliant on FAS (**Figs.4H & S3C**). Considering the lipolytic machinery of CD8⁺T cells, the recent work by O'Sullivan *et al.* ruled out a role for adipose triglyceride lipase (ATGL) in CD8⁺T_M formation and survival [45]; likewise, we found that both young and aged CD8⁺T_M, in contrast to CD8⁺T_N and T_E, were completely resistant to ATGL inhibition (**Fig.S3D**). Rather, hydrolysis of neutral lipids appears to preferentially rely on lysosomal acid lipase (LAL) [45] and in our experiments, blockade of LAL activity by inhibition of lysosomal acidification with 200μM chloroquine demonstrated a comparatively enhanced death of old CD8⁺T_M indicating a greater need for these cells to mobilize FA for FAO (**Figs.4I & S3E**).

Lastly, we wanted to determine how the subtle metabolic alterations in aging CD8⁺T_M populations relate to their overall “metabolic fitness”. Here, our determination of mitochondrial mass and membrane potential failed to document consistent differences but in aggregate, we observed a trend towards enhanced fitness by old CD8⁺T_M (**Fig.S3F** and not shown). In support of this assessment, we also note that PGC-1α, a master regulator of mitochondrial biogenesis most recently shown to improve the bioenergetics of LCMV-specific CD8⁺T cells in a chronic infection model [44], is comparatively elevated at both mRNA and protein levels in aged CD8⁺T_M (**Fig.S3G/H**). In summary, we conclude that the “mixed metabolic phenotype” of long-term CD8⁺T_M populations emerges through a partial reversal of metabolic adaptations that control and accompany the original transition from CD8⁺T_E to young CD8⁺T_M stage, and that the “intermediate” metabolic profile of old CD8⁺T_M likely contributes to their greater recall capacity [1, 5]. Defining a precise inflection point for this “metabolic switch” during CD8⁺T_M aging will be difficult given the delicate and only partial nature of metabolic adaptations, but it is well possible that a net effect of these processes may become discernible only at later stages of the extended CD8⁺T_M evolution [5].

Increasing abundance and precipitous maturation of aging CD8⁺T_M in the splenic white pulp.

The extended maturation of circulating aging CD8⁺T_M populations [1] proceeds in the face of their continued anatomic redistribution but without apparent alteration of total CD8⁺T_M maintained in various lymphoid organs and NLTs [14, 49-51]. Although there are some exceptions to this rule, e.g. the natural decline of influenza virus-specific CD8⁺T_M in lung airways and associated loss of immune protection [52], it has remained unclear how exactly the phenotypic conversion of aging CD8⁺T_M may modulate their trafficking patterns [53]. The gradual re-expression of CD62L in particular [1, 17] would be expected to affect the anatomical distribution of older CD8⁺T_M. For example, young p14 T_{EM} and T_{CM} subsets, distinguished according to CD62L expression and with differential sensitivity to the chemokines CCL19 and CXCL12, preferentially localize to splenic red pulp (RP) and white pulp (WP), respectively [54]. The progressive upregulation of CD62L, CCR7 (CCL19 receptor) and CXCR4 (CXCL12 receptor) by aging splenic CD8⁺T_M [1], confirmed and extended here to blood-borne CD8⁺T_M with different LCMV specificities (**Fig.5A** and not shown), may therefore also promote an altered positioning of these cells within the spleen. To evaluate this possibility, we employed the i.v. injection of fluorochrome-conjugated CD8 β antibody that readily labels CD8⁺T cells found in vascular contiguous compartments (including RP) but not tissue stroma and parenchyma (including WP) [55, 56] (**Fig.S4A**). While the total number of specific CD8⁺T_M in the spleen does not change over time [14], their differentiation according to RP/WP residence demonstrated a pronounced increase from ~15% to ~60% in the WP of aging mice (**Fig.5B**). A concurrent phenotypic stratification of RP/WP subsets according to markers that are substantially up- or down-regulated by aging CD8⁺T_M [1] further revealed striking differences in young mice: the ~15% of young D^bNP₃₉₆⁺ CD8⁺T_M residing in the WP, despite preserving some phenotypic heterogeneity, for the most part already adopted properties comparable to aged CD8⁺T_M (CD27^{hi}, CD62L^{hi}, CD127^{hi}, CXCR3⁺, CD43^{lo}, KLRG1⁻, CX3CR1^{lo}) whereas RP cells (representing ~85% of splenic D^bNP₃₉₆⁺ CD8⁺T_M) exhibited a contrasting and largely “immature” phenotype (**Fig.5C-E**); these differences also pertained to more subtle aspects of CD8⁺T_M aging such as SSC properties and CD8 α expression levels (albeit not cellular size) (**Fig.5E**). In aged LCMV-immune mice, and in agreement with the observation that phenotypic maturation affects both splenic and blood-borne CD8⁺T_M (ref.[1] and **Figs.3A/B & 5A**), the dissimilarity of WP and RP D^bNP₃₉₆⁺ CD8⁺T_M mostly disappeared and both populations presented with an aged phenotype (though the RP subset retained somewhat elevated CD43, KLRG1 and CX3CR1 expression) (**Fig.5C-E**). Nearly identical results were also obtained for young and old D^bGP₃₃⁺ CD8⁺T_M in splenic RP/WP compartments (**Fig.S4B-D**). Lastly, a direct comparison of young and old CD8⁺T_M in the RP confirmed their marked phenotypic differences but the WP subsets, to a lesser degree, also demonstrated evidence for further age-associated phenotype maturation (**Fig.S4E**). Altogether, these observations reveal the gradual emergence of co-regulated complex CD8⁺T_M phenotypes as well as their distinct spatiotemporal segregation that accompanies the more global architectural changes recently reported for the aging murine spleen [57].

Progressive accumulation of aging CD8⁺T_M in peripheral lymph nodes.

Another potential consequence of increasing CD62L, CCR7 and/or CXCR4 expression by aging CD8⁺T_M (**Fig.5A**) is the gradual acquisition of an enhanced LN tropism [58, 59], especially since earlier trafficking studies

have demonstrated the unequivocal requirement for virus-specific CD8⁺T_M-expressed CD62L [60] and chemokine receptors [50] to enter LNs under steady-state conditions. Indeed, a first suggestion in support of this conjecture has come from a recent study that reported a greater proportion of “late” p14 T_M as compared to “early” p14 T_M in inguinal LNs [5]. To examine if the “LN-homing phenotype” of aged CD8⁺T_M confers a preferential redistribution to peripheral LNs *at large*, we enumerated specific CD8⁺T_M in young and old LCMV-immune mice. In the absence of age-associated changes in LN cellularity, we observed an up to 10-fold increase of specific CD8⁺T_M frequencies and numbers in aged mice (**Fig.6A-C**), and a longitudinal analysis of mesenteric LNs (MLN) revealed a slow and continuous accumulation of CD8⁺T_M with an estimated population doubling time of ~190 days (**Fig.6D**). We next assessed the capacity of aging CD8⁺T_M to enter peripheral LNs by performing a competitive homing experiment (**Fig.6E**). In brief, p14 T_M were enriched from young and old LCMV-immune p14 chimeras, differentially labeled with CFSE, combined at a ratio of 1:1, and transferred into naïve B6 recipients. Upon retrieval 48h later, this ratio was skewed to >10:1 in favor of old p14 T_M in peripheral LNs but not blood or spleen demonstrating that aging CD8⁺T_M in fact acquire a capacity for facilitated LN access (**Fig.6E**).

Increased CD62L expression promotes improved LN access for aging CD8⁺T_M.

Similar to polyclonal CD8⁺T_M (**Fig.5A** and ref.[1]), old p14 T_M exhibited higher expression levels of CCR7, CXCR4 and in particular CD62L (**Figs.S5A & 7A**). To determine if CD62L contributed directly to the facilitated LN access of aged CD8⁺T_M, we conducted an *in vivo* homing assay with old p14 T_M under conditions of CD62L blockade and observed an 82-93% reduction of p14 T_M accumulation in peripheral LNs (**Fig.7A**). Similar experiments designed to evaluate the role of chemokine receptors by pretreatment of young and old donor p14 T_M with pertussis toxin (Ptx) revealed, as expected [50], a profound inhibition of p14 T_M trafficking to LNs (**Fig.S5B**). The relative reduction, however, appeared especially pronounced for young p14 T_M indicating a slight advantage for aged p14 T_M to utilize Ptx-insensitive pathways for residual LN access (**Fig.S5B**). The importance of CD62L in conveying an enhanced LN tropism to CD8⁺T_M populations was further illustrated by use of the “virus titration chimeras” discussed above. Following infection of p14 chimeras with escalating titers of LCMV and generation of T cell memory 7 weeks later, p14 T_M expression of CD62L but not CCR7 or CXCR4 significantly declined as a function of increasing viral challenge dosage (**Fig.7B** and data not shown), and reduced CD62L expression correlated with an impaired accumulation of p14 T_M in peripheral LNs (**Fig.7B**). Thus, the LN tropism of CD8⁺T_M, in addition to their survival/Bcl-2 expression (**Fig.2J**), multiple phenotypic and functional properties, and their II^o reactivity [1], can be experimentally controlled in a fashion that accelerates or delays the CD8⁺T_M maturation process *at large*.

Loss of aging CD8⁺T_M from peripheral blood and nonlymphoid tissues.

Based on the above evidence, and in the absence of locally increased homeostatic proliferation (**Fig.3E/F**), the progressive accumulation of aging CD8⁺T_M in secondary lymphoid tissues (**Figs.5B, S4B & 6**) most likely emerged through the redistribution of CD8⁺T_M from other anatomic reservoirs. We estimated,

according to the numbers of specific CD8⁺T_M in the LNs of young and aged LCMV-immune mice (**Fig.6A-C**) as well as the number and variable size of murine LNs [61], that over a period of ~17 months, up to 1×10^6 NP₃₉₆- and 1.9×10^6 GP₃₃-specific CD8⁺T_M were added to the entire LN pool. Given the stable CD8⁺T_M numbers in the spleen [14], the potential sources for the new LN CD8⁺T_M are therefore the blood and marginated pool (BMP), as well as NLTs. In a most recent and comprehensive accounting of organism-wide CD8⁺T_M distribution, based on an evaluation of LCMV-immune p14 chimeras, Steinert *et al.* demonstrated that NLTs and BMP (excluding splenic red pulp) together contain $\sim 6 \times 10^6$ p14 T_M [56]. The p14 model used therein and our B6 system are roughly comparable since flow cytometry-based calculations revealed the presence of $\sim 2.9 \times 10^6$ splenic p14 T_M while we documented a total of $\sim 2.0 \times 10^6$ endogenously generated NP₃₉₆/GP₃₃-specific CD8⁺T_M in the spleen (**Fig.6B/C** and not shown). In regards to LN-residing CD8⁺T_M, however, the models are expected to differ due to increased p14 T_N numbers used for chimera construction [56], correspondingly accelerated upregulation of CD62L by p14 T_M [1], and an experimental evaluation at a somewhat later time points (4-5 months after challenge) [56] that together should result in apparently enhanced LN accumulation. Indeed, the reported grand total of $\sim 2.3 \times 10^6$ p14T_M in peripheral LNs [56] clearly exceeded the $\sim 4.3 \times 10^5$ NP₃₉₆/GP₃₃-specific CD8⁺T_M we found in the LN compartment of B6 mice at ~2 months following LCMV infection (a 5.4-fold difference). With these caveats in mind, we calculated that in the time of ~2-19 months after infection, a less than 2-fold loss from BMP and NLTs could account for the corresponding gain of NP₃₉₆/GP₃₃-specific CD8⁺T_M in the LNs of old LCMV-immune B6 mice.

To test this prediction, we first evaluated the preservation of D^bNP₃₉₆ CD8⁺T_M in the blood by combining data obtained in numerous experiments performed over a period of several years. Interestingly, the aggregate data uncovered an unexpected biphasic loss of blood-borne CD8⁺T_M (**Fig.7C**). In the period of ~7-14 weeks after virus challenge, and thus well after completion of the “contraction phase” in the spleen [14], specific CD8⁺T_M numbers continued to decline in the blood before attaining seemingly stable levels around day 100 after infection. A careful inspection of subsequent time points, however, revealed a subtle decrease of blood-borne CD8⁺T_M with a theoretical population half life of ~3 years (**Fig.7C**). This finding is noteworthy since it evokes, even under experimental conditions that optimize CD8⁺T_M preservation, the natural decline of blood-borne virus-specific CD8⁺T_M in humans [12]. In as much as the cumulative ~60% loss (between weeks 7 and 86) of specific CD8⁺T_M from peripheral blood also reflects a changing CD8⁺T_M abundance in the larger BMP, these cells could provide a relevant contribution to the growing CD8⁺T_M LN pool. The biphasic erosion of blood-borne CD8⁺T_M (**Fig.7C**), however, would seem at odds with the dynamics of CD8⁺T_M accumulation in the LNs (**Fig.6D**). We therefore proceeded with an enumeration of young and old CD8⁺T_M in NLTs (peritoneal cavity, liver, lung, kidney) and observed a 1.4- to 2.7-fold relative reduction of aged CD8⁺T_M numbers (**Fig.7D**). Thus, both theoretical considerations and experimental results support the notion that a loss of aging CD8⁺T_M is not restricted to the lung [5, 52] but involves the BMP and especially NLTs in general.

CD8⁺T_M trafficking and the “tissue resident memory T cell (T_{RM})” paradigm.

How can the above conclusions be reconciled with the notion that NLTs are preferentially populated by non-recirculating T_{RM} [62]? According to Steinert *et al.*, ~9% of $CD8^+T_M$ found in NLTs can in fact recirculate, a fraction that is lower in some (e.g., lung) but higher in other (e.g., liver) compartments [56]. These calculations are based on parabiosis experiments that were conducted, similar to multiple other studies, over a period of just ~1 month [56]. A notably longer observation period was employed by Jiang *et al.* who found that the frequencies of skin $CD8^+T_{RM}$ in the donor parabiont declined by ~2-fold between 8 and 24 weeks after surgery suggesting limits to $CD8^+T_{RM}$ longevity and/or mobilization of the $CD8^+T_{RM}$ compartment [63]. The latter observation is not only in agreement with a classic study that reported a trend towards continued equilibration of $CD8^+T_{RM}$ within intestinal lamina propria and epithelium for at least 8 weeks [50] but also consistent with our experiments that compare $CD8^+T_M$ populations recovered from NLTs at time points separated by ~18 months and thus may offer sufficient time for some $CD8^+T_{RM}$ to re-enter the circulation. Of further importance is the recent observation that traditional flow cytometry-based methods of $CD8^+T_M$ quantification in NLTs markedly underestimate the true number of $CD8^+T_M$ found in these tissues [56]. While our quantification of young and old $CD8^+T_M$ in liver, lung and kidney therefore cannot accurately account for absolute $CD8^+T_M$ numbers, it is the *relative* reduction of $CD8^+T_M$ recovered from the NLTs of aged LCMV-immune animals, readily revealed even by use of flow cytometry, that is important for the present context. Consistent with this interpretation, we also observed an age-associated decrease of $CD8^+T_M$ numbers in the peritoneal cavity (**Fig.7D**), an organ that is not subject to the inefficiency of $CD8^+T_M$ recovery from solid NLTs. Finally, in considering the role of $CD8^+T_{RM}$ as highly effective first responders to infections re-encountered at body surfaces [64] and the established role of LN-residing $CD8^+T_M$ as direct precursors for IL^0 $CD8^+T_E$ expansions, it is worth noting that LN $CD8^+T_M$ themselves also act as “gate-keepers” and immediate effectors capable of curtailing peripheral infections and preventing systemic viral spread [65]. In fact, following a footpad LCMV challenge of mice that received limiting numbers of young vs. old $CD8^+T_M$, we found that only the latter population prevented systemic dissemination of the virus (not shown). Therefore, the gradual accumulation of aging $CD8^+T_M$ in peripheral LNs, even at the expense of $CD8^+T_M$ in NLTs, may represent a progressively enhanced “strategic positioning” in anatomic locations that constitute a critical site for both local pathogen control and the coordination of effective recall expansions [66].

Increased accumulation of old $CD8^+T_M$ in primary lymphatic tissues.

Considering the tissue redistribution of aged $CD8^+T_M$ in their overall numerical context (**Figs.5B, 6 & 7C/D**), it appears that the relative loss from NLTs and blood might even exceed the corresponding gain in peripheral LNs. A clue to another anatomic site for potential $CD8^+T_M$ accrual comes from the increased CXCR4 expression by old antiviral $CD8^+T_M$ (**Figs.5A, S5A** & ref.[1]). CXCR4 is held to be a “BM homing receptor” and consistent with this notion, recent work demonstrated that conditional CXCR4 deletion in LCMV-specific T cells resulted in a reduced abundance of $CD8^+T_M$ populations especially in the BM [67]. Thus, it is conceivable that greater CXCR4 expression levels by aged $CD8^+T_M$ preferentially promote increased BM access, an important anatomic niche for $CD8^+T_M$ [68]. Indeed, the frequencies and numbers of $D^bNP_{396}^+$ and $D^bGP_{33}^+$ $CD8^+T_M$ retrieved from the BM of aging LCMV-immune mice roughly doubled over a period of ~1.5 years (**Fig.7D**) though in contrast to LNs, accumulation of aging $CD8^+T_M$ in the BM was independent of CD62L (**Fig.S5C**). In

competitive homing experiments similar to those shown in **Fig.6E** but conducted here with endogenously generated CD8⁺T_M, aged CD8⁺T_M also displayed a slightly enhanced BM tropism; at the same time, their facilitated LN access was expectedly more pronounced (**Fig.7E**).

Finally, the apparently generalized pattern of age-associated increasing CD8⁺T_M abundance in both secondary (splenic WP, LN) and primary (BM) lymphatic tissues also warranted an analysis of the thymus. Interestingly, we observed an almost 2-fold *relative* increase of old over young CD8⁺T_M populations for this primary lymphatic organ (counts normalized to 10⁶ cells); due to thymic involution, however, absolute numbers of aged CD8⁺T_M were expectedly reduced, here by a factor of ~2.5 (**Fig.7F**).

CONCLUSIONS

As detailed in our recent work on CD8⁺T cell memory [1], aging of established antiviral CD8⁺T_M populations introduces a series of cumulative molecular, phenotypic and functional changes that collectively confer naïve-like T cell traits, greater proliferative potential and protective capacities onto old CD8⁺T_M populations. To account for these sweeping processes in a simple fashion, we have introduced the “rebound model” of CD8⁺T_M maturation according to which the extent of initial CD8⁺T_E differentiation directly determines the kinetics of protracted CD8⁺T_M “de-differentiation” [1]. We now demonstrate that this remodeling process also impinges on the homeostasis of CD8⁺T_M as evidenced by their evolving survival capacity, metabolic adaptations and microanatomic redistribution. Here, both the Bcl-2-dependent enhancement of apoptosis resistance and the accumulation of old CD8⁺T_M in lymphoid tissues (including the CD62L-guided peripheral LN access/residence) as a likely consequence of a redistribution from NLTs and blood are consistent with the progressive modulation of aging CD8⁺T_M phenotypes, in particular at the level of increasing CD62L, CD122, CD127, CCR7 and CXCR4 expression [1-3, 5, 17]. We further document that the gradual acquisition of mature phenotypes by aging CD8⁺T_M populations proceeds through co-regulated modulation of receptor/ligand expression and at a pace that is contingent on the specific microenvironment (i.e., accelerated in splenic WP, delayed in RP). In addition, all of these dynamics are readily captured by the basic tenet of the “rebound model” that posits a broad harmonization of CD8⁺T_M and T_N traits while simultaneously reinforcing the development of a simple CD8⁺T_M core signature [1].

The imperviousness of aging CD8⁺T_M to changes of their basal homeostatic proliferation rates, however, was unexpected. Our results document a simple association between cytokine receptor (CD122/CD127) expression levels and functionality, and the importance of CD127 abundance as well as the intermittent rather than continuous IL-7 signaling for the homeostasis of naïve CD8⁺T cell populations has been illustrated by the work of A. Singer’s group [69]. Yet we previously noted a lack of association between CD127/CD122 expression levels on CD8⁺T_M and their tissue-specific pace of homeostatic turnover [38], and the heightened responsiveness of aged CD8⁺T_M to IL-7 and IL-15 as shown here failed to confer increased homeostatic proliferation rates. Old CD8⁺T_M may therefore have adopted an exquisite balance with age-associated changes

in various tissue microenvironments; the homeostasis of CD8⁺T_N and pathogen-specific CD8⁺T_M, though reliant on the same cytokines (IL-7, IL-15), may be regulated in a differential manner; or other factors contributing to the regulation of CD8⁺T_M homeostasis may become more dominant over time. We also note that changing levels of CD8⁺T_M-expressed CXCR4, recently proposed to control the homeostatic turnover of CD8⁺T_M [67], had no apparent impact on their homeostatic self-renewal over time. A recent analysis of human CD45RO⁺CD8⁺T_{MP} populations also found no differences in homeostatic turnover rates between young and healthy elderly individuals [70].

Though subtle, the metabolic adaptations of aging CD8⁺T_M would appear to contradict the “rebound model” since they are characterized by a partial re-acquisition of CD8⁺T_E-like profiles, in particular an increase of glucose utilization [40]. Yet the shift towards enhanced glucose uptake, decreased neutral lipid content as well as reduced FA and LDL uptake also indicates a gradual return, albeit incomplete, towards respective CD8⁺T_N capacities. Nevertheless, CD8⁺T_N consistently displayed greater sensitivity to *in vitro* FAS and FAO inhibition than either young or old CD8⁺T_M suggesting that the latter cells’ distinctive and evolving metabolic profiles should be considered part of the memory “core signature” that distinguishes CD8⁺T_M from T_N.

Three aspects of CD8⁺T_M homeostasis will require further clarification to define relevant age-associated adaptations and their potential impact on I^o reactivity and immune protection in more detail. 1., the progressive conversion of aging CD8⁺T_M documented primarily for spleen and blood [1-3, 5] will have to be considered for other tissues [62], in the context of continued CD8⁺T_M subset migration vs. extended tissue residence (including the precise developmental relations and potential phenotypic/functional modulation of CD8⁺T_M populations as they enter and exit various tissues) [38, 71, 72], and for human CD8⁺T_M [73]. 2., the transcriptional control of CD8⁺T_M aging is another topic of broad interest. For example, among the major transcriptional regulators of CD8⁺T_{E/M} differentiation predicted on the basis co-regulated gene expression in activated CD8⁺T cells [74] are several TFs (*Tcf4*, *Zeb2*, *Rora*, *Hif1a*, *Arntl*) that also demonstrate progressive downmodulation in aging CD8⁺T_M [1]. In agreement with this observation, enhanced activity of hypoxia-inducible factors (HIFs) was recently shown to sustain a CD8⁺T_E-like state [75] while *Zeb2*-deficiency accelerated CD8⁺T_{CM} formation [76]; the extent to which the evolution of complex TF expression profiles in aging CD8⁺T_M supports a return to a CD8⁺T_N-like transcriptional program while simultaneously reinforcing the emergence of a highly focused CD8⁺T_M “core signature” is currently under investigation. 3., in conjunction with transcriptional regulation, epigenetic DNA and chromatin modifications provide irreducible contributions to the specification of CD8⁺T_M fates [77]. Though it remains unclear if established CD8⁺T_M are subject to epigenetic modulations under steady-state conditions, it is conceivable that exposure to or withdrawal from different microenvironmental cues may alter the epigenetic landscape of aging CD8⁺T_M.

In summary, the present work confirms and expands the central tenets of the “rebound model” [1] by documenting the fundamentally temporal nature of CD8⁺T_M homeostasis and identifying associated determinants for improved CD8⁺T_M survival, metabolic alterations and lymphoid tissue homing that collectively brace aged CD8⁺T_M for enhanced I^o expansion and immune protection. The dynamic adaptations of long-term

CD8⁺T cell memory and the possibility to accelerate or delay these processes *at large* [1] provides an experimental framework for the focused interrogation of suitable targets that may be exploited for the prophylactic or therapeutic modulation of specific CD8⁺T_M responses. To this end, we have explored elsewhere the specific contribution of 16 molecular pathways to the improved II^o reactivity of aged CD8⁺T_M populations (manuscripts in preparation).

METHODS

Ethics statement

All procedures involving laboratory animals were conducted in accordance with recommendations in the “Guide for the Care and Use of Laboratory Animals of the National Institutes of Health”, the protocols were approved by the Institutional Animal Care and Use Committees (IACUC) of the University of Colorado (permit numbers 70205604[05]1F, 70205607[05]4F and B-70210[05]1E) and Icahn School of Medicine at Mount Sinai (IACUC-2014-0170), and all efforts were made to minimize suffering of animals.

Mice, virus and challenge protocols

C57BL6/J (B6), congenic B6.CD90.1 (B6.PL-*Thy1^a*/CyJ) and congenic B6.CD45.1 (B6.SJL-*Ptprc^a**Pepc^b*/BoyJ) mice were purchased from The Jackson Laboratory; p14 TCRtg mice were obtained on a B6.CD90.1 background from Dr. M. Oldstone (CD8⁺T cells from these mice [“p14 cells”] are specific for the dominant LCMV-GP₃₃₋₄₁ determinant restricted by D^b). We only used male mice in this study to avoid potential artifacts that may arise in gender mismatched adoptive transfer settings. LCMV Armstrong (clone 53b) was obtained from Dr. M. Oldstone and stocks prepared by a single passage on BHK-21 cells; plaque assays for determination of virus titers were performed as described/referenced [14]. For I^o challenges, 8-10 week old mice were infected with a single intraperitoneal (i.p.) dose of 2x10⁵ pfu LCMV Armstrong; for II^o challenges, naïve recipients (aged 8-10 weeks) of various CD8⁺T_M populations were inoculated with 2x10⁵ pfu LCMV Arm i.p. All mice were housed under SPF conditions and monitored for up to ~2 years. Aging LCMV-immune mice were excluded from our study if they presented with 1., gross physical abnormalities such as lesions, emaciation and/or weight loss, 2., lymphatic tumors as indicated by enlarged LNs at time of necropsy or 3., T cell clonal expansions within the virus-specific CD8⁺T_M compartment (D^bNP₃₉₆⁺, D^bGP₃₃⁺ or D^bGP₂₇₆⁺). According to these criteria, up to ~30% of aging mice were excluded from the study.

Tissue processing, cell purification and adoptive transfers (AT)

Lymphocytes were obtained from blood, spleen, lymph nodes (LNs), thymus, peritoneal cavity and bone marrow (BM) according to standard procedures; for an estimate of total BM cells, the content from one femur was multiplied with a coefficient of 15.8 [38] (**Fig.7D**). For isolation of lymphocytes from solid NLTs (liver, lung, kidney), terminally anesthetized mice were sacrificed by total body perfusion with PBS and subsequent organ processing and gradient centrifugation as described [38]. Enrichment of splenic T cells was performed with magnetic beads using variations and adaptations of established protocols. 1., for construction of p14 chimeras [1], p14 T_N (CD90.1⁺) were enriched from spleens of naïve p14 mice by negative selection (EasySep Mouse CD8⁺T Cell Enrichment Kit, StemCell Technologies) and transferred i.v. into B6 recipients at indicated numbers prior to LCMV infection 2-24h later (**Fig.2J**: 2x10²–2x10⁵ or 1x10⁴; **Figs.3C, S2C & S5A/B**: 5x10⁴; **Figs.6E, 7A & S5C**: 2x10³, **Fig.7B**: 1x10⁴). 2., purification of p14 T_{E/M} for microarray analyses is described in ref.[1]. 3.,

enrichment of CD8⁺T_M from LCMV-immune B6 and B6-congenic donors was performed by depletion of B220⁺ cells (Miltenyi, Invitrogen/Dynal or StemCell Technologies) followed by 1:1 combination at the level of D^bNP₃₉₆⁺ CD8⁺T_M, i.v. AT of mixed populations containing 2x10³ D^bNP₃₉₆⁺ congenic CD8⁺T_M each into naïve congenic recipients, and challenge with LCMV (**Fig.2H**).

Flow cytometry

All reagents and materials used for analytical flow cytometry are summarized in **Table S1**, and our basic staining protocols are described and/or referenced in ref.[1]; in some cases, expression levels were normalized by dividing the GMFI of experimental by the GMFI of isotype control stains (**Fig.2I**). Additional methodologies employed here include the use of various fluorescent dyes/probes (PI, 7AAD, YO-PRO-1, Zombie dyes, DiOC₆(3), dihydroethidium [HE], Alm Alx488, ThiolTracker Violet, Glut1.RBD.GFP [stained at 37°C for detection of surface Glut1]), Mito Tracker Green [MTG], tetramethylrhodamine [TMRE] and JC-1 dye according to manufacturer recommendations and/or published protocols [21, 78, 79] (**Figs.2, 4E, S3F** and not shown), and the detection of certain intracellular antigens using methanol permeabilization (pSTAT5, Glut1, Glut3) as described [80] or the ebioscience Foxp3/TF buffer set (PGC-1α) (**Figs.3C/D, 4E, S2A & S3H**). Lipid content and lipid/glucose uptake were determined by incubation with Bodipy 493/503 (0.5μg/ml PBS, 10min. at RT) or 37°C culture in complete RPMI in the presence of Bodipy FL C16 (overnight at 0.5μg/ml), Bodipy LDL (30min. at 10μg/ml), or 2-NBDG (2h at 100μg/ml) prior to cell surface stains and acquisition (**Fig.4E/G**). Intravascular staining of CD8⁺T cells was adapted from the methodology developed by Anderson *et al.* [55] (i.v. injection of 4μg anti-CD8β-PE [53-5.8] followed by euthanasia 4-5 min later, tissue harvesting/processing and staining with anti-CD8α-BV421 or -PerCP-Cy5.5 [53-6.7], other cell surface receptor/ligand antibodies and MHC-I tetramers; **Figs.5B-E & S4**). Samples were acquired on FACSCalibur, Accuri C6, Canto, LSRII or LSR Fortessa X-20 flow cytometers (BDBiosciences) and analyzed with DIVA (BDBiosciences) and/or FlowJo (TreeStar) software; dimensionality reduction and data display for polychromatic flow cytometry was performed using the Cytobank platform and the t-SNE algorithm viSNE [81] (input parameters: FSC/SSC properties and CD8α, CD8β, CD27, CD43 (S7), CD62L, CD127, KLRG1, CXCR3, CX3CR1 mean expression levels of young or old D^bNP₃₉₆⁺ and D^bGP₃₃⁺ CD8⁺T_M populations).

Microarray analyses and qRT-PCR

Details for microarray analyses of highly purified p14 T_{E/M} populations are found in ref.[1], and selected data are shown here in **Figs.1C/D, 4A/D, S1 & S3A/G**. Gene set enrichment analyses (GSEA) were performed based on filtered data sets obtained for aging p14 T_M (d46, d156, d286 and d400) [1] against 186 KEGG gene sets/pathways (<http://software.broadinstitute.org/gsea>) (**Figs.1A, 2E, 4C, S2B & S3B**). We treated time series as continuous phenotypes and used Pearson's correlation to determine ranks for each gene. Enrichment scores (ES) were obtained as the maximum deviation from zero of $P_{hit} - P_{miss}$, where P_{hit} and P_{miss} are fractions of genes in or not in specific gene sets weighted by their correlations up to a given position in the rank; p values were estimated from random permutation tests by comparing random ES versus observed ES [82]. For qRT-

PCR (**Fig.S2C**), RNA isolation and DNaseI digestion was performed with spleen, LN and BM cells stored in RNA later using RNAqueous-4PCR kit per manufacturer protocol (Ambion/Life Technologies). RNA integrity was evaluated on a RNA Nano chip run on a Bioanalyzer 2100 (Agilent Technologies); RNA integrity numbers (RIN) for all samples were 8.2-9.6. The cDNA first strand transcription was performed using 370ng of total RNA with the iScript cDNA synthesis kit following manufacturer protocol (BioRad). *I17* and *I15* primers were obtained from PrimerBank (<http://pga.mgh.harvard.edu/primerbank/>). Primer sequences for the SYBR green qPCR were as follows: *I17* (PrimerBankID 6680433a1) forward (5-TTCCTCCACTGATCCTTGTCT-3) & reverse (5-AGCAGCTTCC TTTGTATCATCAC-3), *I15* (PrimerBankID 6680407a1) forward (5-ACATCCATCTCGTGCTACTTGT-3) & reverse (5-GCCTCTGTTTTAGGGAGACCT-3), *Gapdh* forward (5-AATGAAGGGGTCATTGATGG-3) & reverse (5-AAGGTGAAGGTCCGAGTCAA-3). Quantitative PCR was performed on a Roche LightCycler 480II Real Time PCR instrument, using PerfeCta SYBR Green (Quanta Biosciences). PCR was carried out in a 20ul volume and a final concentration of 1X reaction buffer, 385nM forward and reverse primers and 1.0ul cDNA reaction. Four log10 dilutions of pooled sample cDNA template were prepared and used for primer validation and standard curve reference. All sample reactions were performed in triplicate with NTC reactions for all primer sets on a single plate. PCR cycling parameters were as follows: hot-start at 95°C for 2min30sec, 45 cycles of 95°C for 15sec, 60°C for 35sec, followed by a dissociation curve measurement from 65°C to 95°C. Relative comparison analysis with efficiency correction was performed using the LC480II data collection software release 1.5.0.39 SP4. Melt curve analysis for all assays verified single product amplification and absence of primer dimers. NTC reactions for all primer sets were >5Cq from all control and unknown samples.

In vitro survival assays

Single cell suspensions prepared from spleen or lymphocyte-purified (Cedarlane) PBMCs were cultured for 12-48h in RPMI supplemented with 10% FCS but in the absence of added growth or survival factors (**Fig.2B/D**); in some cases, titrated amounts of pharmacological inhibitors ABT-737 (Abbott), C75 (Cayman), atglistatin (Cayman), chloroquine (Sigma) or vehicle were added to cultures (**Figs.2H, 4H/I & S3C-D**). CD8⁺T cell survival was subsequently determined by combined CD8α, congenic marker, MHC-I tetramer or CD44, and viability stains (Annexin V/propidium iodide [PI] or 7AAD, or Zombie dyes). Absolute numbers of viable CD8⁺T cell subsets were calculated using Countess (Invitrogen) or Vi-Cell (Beckmann Coulter) automated cell counters.

In vivo homing assays

For competitive homing assays, splenic p14 T_M were enriched from young and old LCMV-immune p14 chimeras, differentially labeled with CFSE, mixed at a ratio of 1:1 and, depending on experiments, populations containing 1.1-4.2x10⁵ p14 T_M each were injected i.v. into B6 recipients; 42-48h later, transferred p14 T_M were retrieved and enumerated in LNs and other tissues (**Figs.6E & S5B**). Homing assays using endogenously generated CD8⁺T_M populations were conducted in an analogous fashion using 5-6x10⁴ D^bNP₃₉₆⁺ CD8⁺T_M each, B6.CD45.1 recipients and retrieval of donor cells from various tissues 20h later (**Fig.7E**). In some cases, mixed

donor populations were incubated for 1h in complete RPMI (1.5×10^7 cells/ml) in the presence or absence of 25ng/ml pertussis toxin (RnD Systems) prior to washes and transfer (**Fig.S5B**). For trafficking studies under conditions of CD62L blockade (**Fig.7A & S5C**), B6 mice were treated with a single i.p. injection of 200 μ g α CD62L (MEL-14) or rIgGa control (RTK2758) 2h before transfer of $\sim 5 \times 10^5$ aged p14 T_M and retrieval 48h later. Further details about all antibodies are provided in **Table S1**.

Statistical analyses

Data handling, analysis and graphic representation was performed using Prism 6.0c (GraphPad Software). All data summarized in bar and line diagrams are expressed as mean $\pm$ 1 standard error (SEM), and asterisks indicate statistical differences calculated by Student's t-test (unpaired or paired), or one-way ANOVA with Dunnett's multiple comparisons test, and adopt the following convention: *: $p < 0.05$, **: $p < 0.01$ and ***: $p < 0.001$.

ACKNOWLEDGEMENTS

We wish to thank the NIH Tetramer Core Facility for provision of biotinylated MHC:peptide monomers, Dr. D. Hildeman for advice about the use of ABT-737, Dr. C. Buettner for provision of atglistatin, R. Wong for help with qRT-PCR analyses, and Dr. P. Marrack for the gift of the BIM antibody. This work was supported by NIH AG026518 and AI093637, JDRF CDA 2-2007-240, and DERC P30-DK057516 (DH), American Heart Association 13SDG14510023 (ETC), and NIH training grants T32 AI07405, T32 AI052066 and T32 DK007792 (BD); the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, and the authors declare no competing financial interests. Due to the wide-ranging nature of topics discussed herein we have frequently relied on the citation of review rather than original research articles and wish to apologize to the authors whose work is not explicitly mentioned.

FIGURE LEGENDS

Figure 1. Temporal regulation of major survival-associated components by aging CD8⁺T_M. **A.**, GSEAs were performed with p14 T_M data sets (d46-d400 after virus challenge) as described in Methods and demonstrate a relative depletion of genes within the KEGG apoptosis module for aged p14 T_M (normalized enrichment score [NES]: -1.04); the corresponding heat map displays relative expression levels of GSEA-ranked genes within that module. **B.**, staining/gating strategy and representative Bcl-2 and BIM expression data in young and old CD8⁺T_M. **C. & D.**, progressive modulation of survival/apoptosis-related mRNA (p14T_{E/M}) and protein (D^bNP₃₉₆⁺ CD8⁺T_{E/M}) expression levels; Bcl-2:BIM ratios were calculated by division of respective GMFI (geometric mean of fluorescence intensity) values and are shown for both total D^bNP₃₉₆⁺ CD8⁺T_M and subsets stratified according to CD62L expression. The vertical gray bars indicate the transition period from CD8⁺T_E stage (d8) to early T_M stage (d42), and significant differences emerging over the course of the memory phase (comparing young and older specific CD8⁺T_M populations by one-way ANOVA with Dunnett's multiple comparisons test) are highlighted in red (up-regulation) or green (down-regulation); the parenthetical asterisk in the *Bcl2l11* graph indicates significance between d46 and d400 p14T_M as calculated by Student's t-test (n≥3 individual mice per time point and experiment).

Figure 2. Life & death of aging CD8⁺T_M. **A.**, viability of blood-borne D^bNP₃₉₆⁺ CD8⁺T_M as assessed directly *ex vivo* (dot plots gated on CD8⁺T cells). **B.**, survival of splenic NP₃₉₆-specific CD8⁺T_M was determined after 24-48h *in vitro* culture in the absence of added survival/growth factors ("withdrawal apoptosis", dot plots gated on D^bNP₃₉₆⁺ CD8⁺T_M); data from 2 separate experiments display apoptosis/death (middle) or survival (right) of D^bNP₃₉₆⁺ CD8⁺T_M as a function of age. **C.**, reactive oxygen species (ROS) production capacity of blood-borne D^bNP₃₉₆⁺ CD8⁺T_M. **D.**, mitochondrial membrane potential (ΔΨ_m) of D^bNP₃₉₆⁺ CD8⁺T_M was measured as a function of time after LCMV challenge and duration of *in vitro* culture (0-24h). **E.**, GSEA analysis of glutathione (GSH) metabolism (normalized enrichment score [NES]: 1.28). **F.**, intracellular GSH levels of aging blood-borne D^bNP₃₉₆⁺ CD8⁺T_M. **G.**, modulation of cell surface thiol levels by aging D^bNP₃₉₆⁺ CD8⁺T_M as determined by maleimide-Alx488 staining (the insert compares young [gray: d43] and old [black: d575] D^bNP₃₉₆⁺ CD8⁺T_M); plasma thiol groups were quantified in young and old LCMV-immune B6 mice as indicated using 5,5'-dithiobis(2-nitrobenzoic acid), and data are expressed in relation to a GSH standard. **H.**, CD8⁺T cells enriched from young and old congenic mice were mixed 1:1 at the level of D^bNP₃₉₆⁺ CD8⁺T_M and cultured for 48h in the absence or presence of the Bcl-2 antagonist ABT-737. Left: dot plots gated on total CD8⁺T cells; middle: viability of young vs. old CD8⁺T cells as a function of ABT-737 concentration; right: survival of D^bNP₃₉₆⁺ CD8⁺T_M is displayed as the relative preponderance of young vs. old populations after 48h of culture (the dotted line indicates the original input ratio of Y:O = 49:51%). **I.**, Bcl-2 expression levels of blood-borne I^o (H: host) and II^o (Y vs. O) D^bNP₃₉₆⁺ CD8⁺T_{E/M} generated in the same animals and analyzed on d8 (left) and d33 (right) after mixed AT/re-challenge. **J.**, Bcl-2 expression by p14 T_M (d44-49) as a function of original p14 T_N input number (left) or LCMV challenge dosage (right); n≥3 individual mice per time point in 2-4 independent experiments.

Figure 3. CD127/CD122 expression, signaling and homeostatic proliferation of aging CD8⁺T_M. **A.**, cohorts of young adult B6 mice were challenged with LCMV in a staggered fashion and contemporaneous analyses of aging CD8⁺T_M populations were conducted with peripheral blood. Dot plots are gated on CD8⁺T cells and display CD127/IL-7Ra expression by young and old D^bGP₃₃⁺ (top) and D^bNP₃₉₆⁺ (bottom) CD8⁺T_M; note that data for D^bGP₃₃⁺ and D^bNP₃₉₆⁺ CD8⁺T_M were generated with different flow cytometers such that GMFI values between these populations cannot be directly compared (n=4 mice/time point). **B.**, temporal regulation of CD122/IL-2Rb (also part of the IL15R complex) expression by blood-borne D^bGP₃₃⁺ and D^bNP₃₉₆⁺ CD8⁺T_M; data organization as in panel A. **C.**, IL-7 and IL-15 responsiveness of young and old p14 T_M as determined by STAT5 phosphorylation (15min *in vitro* cytokine exposure); histograms are gated on p14 T_M (gray: no cytokine, thin black tracing: IL-15 [0.2ng/ml], thick black line: IL-7 [0.2ng/ml]). Note that maximal respective STAT5 phosphorylation required 0.2ng/ml rIL-7 but ~10ng/ml rIL-15 (not shown). **D.**, *ex vivo* pSTAT5 levels of aging CD8⁺T_M. **E.**, Ki67 expression by young and old blood-borne D^bNP₃₉₆⁺ CD8⁺T_M (values indicate average percentage of Ki67⁺ cells [n=5-9 mice; p=ns]). **F.**, homeostatic proliferation of GP₃₃-specific CD8⁺T_M in different tissues of young and old LCMV-immune B6 mice was assessed with a 7-day *in vivo* BrdU pulse (combined data from 2 independent experiments). **G.**, frequency (top) and homeostatic proliferation (bottom, 7-day BrdU pulse) of CD62L^{hi} and CD62L^{lo} GP₃₃-specific CD8⁺T_M subsets in spleen and MLN of young LCMV-immune B6 mice (n≥3 individual mice per time point and experiment). Statistical differences were calculated using one-way ANOVA with Dunnett's multiple comparisons test (panels A/B), or Student's t-test (panels C-G).

Figure 4. Metabolic adaptations of aging CD8⁺T_M. **A.**, temporal regulation of *Mtor* and *Rps6* expression by aging p14 T_M. **B.**, expression of mTOR and phosphorylated Rps6 (pS6) by young and old LCMV-specific CD8⁺T_M. **C.**, GSEAs were conducted with previously generated data sets on aging p14 T_M as detailed in Methods, and the panel summarizes the temporally regulated gene sets progressively enriched or depleted within the KEGG metabolism module (statistical significance in only three pathways is indicated by asterisks). **D.**, temporal regulation of *Slc2a1* and *Slc2a3* expression by aging p14 T_M. **E.**, expression levels of total Glut1 (intracellular stain), surface Glut1 (Glut1.RBD.GFP stain) or total Glut3 were determined for CD44^{lo}CD8⁺T_N (d0), D^bNP₃₉₆⁺ CD8⁺T_E (d8) as well as indicated young and old D^bNP₃₉₆⁺ CD8⁺T_M in multiple contemporaneous experiments conducted with splenic or blood-borne CD8⁺T cell populations (histograms are gated on indicated “live” [zombie] CD8⁺T cell subsets). Bottom panel: glucose uptake by indicated CD8⁺T cell populations was quantified using the fluorescently-labeled deoxyglucose analog 2-NBDG. **F.**, expression of insulin receptor (CD220) by indicated CD8⁺T cell populations. **G.**, neutral lipid content as well as long-chain FA and LDL uptake by indicated CD8⁺T cell populations was quantified using Bodipy 493/503, Bodipy FL C16 or Bodipy-LDL staining, respectively (overall experimental design and data display as detailed in panel E). **H.**, spleen cells from naïve mice and LCMV-immune mice were cultured for 24h under conditions of “withdrawal apoptosis” in the presence of titrated amounts of the FASN inhibitor C75 or vehicle. To account for the differential survival capacity of the different CD8⁺T cell subsets in the absence of inhibitor (O CD8⁺T_M > Y CD8⁺T_M > CD8⁺T_N > CD8⁺T_E; **Fig.2G** and not shown), their relative survival in vehicle cultures was normalized to 100%. Bottom panel: relative survival of indicated CD8⁺T_M populations at 30μM C75. **I.**, impact of the LAL inhibitor chloroquine on CD8⁺T cell survival; experimental design as in panel H. Statistical analyses were performed using one-way

ANOVA with Dunnett's multiple comparisons test (panels A, D, E, G and H/I bar diagrams) or Student's t-test (panel B) comparing indicated CD8⁺T cell populations (the parenthetical asterisk in the upper bar diagram in panel G indicates significance by Student's t-test but not ANOVA); n≥3 individual mice per group for all experiments conducted independently 2-3 times.

Figure 5. Increasing abundance and accelerated maturation of aging CD8⁺T_M in the splenic WP. **A.**, temporal regulation of CCR7 (top) and CXCR4 (bottom) expression by D^bGP₃₃⁺ (left) and D^bNP₃₉₆⁺ (right) CD8⁺T_M in peripheral blood; dot plots are gated on CD8⁺T cells and CXCR4 expression was revealed by intracellular stains (n=4 mice/time point). Although the subtle increase of CD8⁺T_M-expressed CXCR4 is not statistically significant in the present data sets, the trend is apparent and in agreement with significant differences shown in related experiments (**Fig.S5A** and ref.[1]). **B.**, relative abundance of D^bNP₃₉₆⁺ CD8⁺T_M in the splenic WP of young and aged mice as revealed by intravascular CD8 staining. **C.**, phenotypic properties of young and old D^bNP₃₉₆⁺ CD8⁺T_M in splenic RP vs. WP. **D.**, viSNE rendering of the D^bNP₃₉₆⁺ CD8⁺T_M phenotype space in RP vs. WP of young (top) and old (bottom) LCMV-immune mice. **E.**, individual phenotypic characteristics of D^bNP₃₉₆⁺ CD8⁺T_M RP and WP populations in young (left) and old (right) mice (panels B-E: n≥3 mice/time point analyzed in 2 separate experiments; for further details on intravascular staining and viSNE analyses, see Methods).

Figure 6. Progressive accumulation of aging CD8⁺T_M in peripheral LNs. **A.**, LNs were harvested from young and old LCMV-immune B6 mice, restimulated with GP₃₃ (left) or NP₃₉₆ (right) peptides and stained for CD8α and intracellular IFNγ. Values indicate frequencies of epitope-specific CD8⁺T_M among all LN cells (similar results were obtained for CD8⁺T_M specific for the subdominant GP₂₇₆ epitope, not shown). CeLN: cervical LN, AxLN: axillary LN, BrLN: brachial LN, MLN: mesenteric LN, InLN: Inguinal LN, PoLN: popliteal LN. **B.**, cellularity of spleen and indicated LNs obtained from young and old LCMV-immune B6 mice. **C.**, numbers of GP₃₃- (left) and NP₃₉₆-specific (right) CD8⁺T_M in spleen and peripheral LNs of young and old mice (n=3; data from 1/4 independent experiments). **D.**, progressive accumulation of GP₃₃-specific CD8⁺T_M in the MLN of aging LCMV-immune mice (n=2-4 for each time point, asterisks indicate statistical significance comparing young [~d50] and older mice). Comparative non-linear regression analyses for the period from ~d50-d650 revealed a best curve fit using an exponential growth model (r²=0.88) and thus permitted the calculation of a population doubling time of t_D=188 days. **E.**, splenic p14 T_M populations enriched from young (d51) and old (d533) p14 chimeras were differentially labeled with CFSE, combined at a ratio of 1:1 (upper left histogram), transferred i.v. into B6 recipients and retrieved 48 hours later from various tissues (experimental flow chart and other histograms); the bar diagram summarizes the relative composition of young and old p14 T_M populations recovered from blood and indicated LNs (representative data from 1/2 similar experiments).

Figure 7. Redistribution of aging CD8⁺T_M from NLTs to lymphoid tissues. **A.**, upper left/middle: CD62L expression of young and aged p14 T_M used for homing assays in **Fig.6E** (asterisks indicate significant differences with n=4-5 mice), and of old donor p14 T_M used for CD62L blocking studies. Upper right: experimental flow chart for p14 T_M trafficking experiments. Bottom: enumeration of p14 T_M in spleen and LNs of

recipient mice treated with α CD62L or control antibodies; the values indicate the extent of reduced LN trafficking as a consequence of CD62L blockade. **B.**, left: experimental flow chart depicting the generation of “virus titration chimeras”; right: CD62L expression levels of p14 T_M (d49) as a function of original virus challenge dosage. Bottom enumeration of p14 T_M in spleen and LNs of LCMV-immune p14 chimeras infected with 2×10^5 or 2×10^7 pfu LCMV. **C.**, subtle decline of aging D^bNP₃₉₆⁺ CD8⁺T_M in peripheral blood (combined data from multiple independent experiments); the theoretical population half-life beyond d100 after infection was calculated to be ~3 years. **D.**, quantification of D^bNP₃₉₆⁺ CD8⁺T_M isolated from lymphatic and nonlymphoid tissues of young and old LCMV-immune B6 mice. Dot plots and histograms are normalized to display 1.7×10^4 CD45⁺ cells with values indicating the fraction of D^bNP₃₉₆⁺ CD8⁺T_M; the bar diagrams display representative results from two independent experiments. **E.**, homing of young and old D^bNP₃₉₆⁺ CD8⁺T_M was assessed by differential CFSE labeling of donor populations, combination at a ratio of 1:1 (upper left histogram), i.v. transfer of 5.5×10^4 D^bNP₃₉₆⁺ CD8⁺T_M each into B6.CD45.1 recipients, and retrieval from indicated tissues 20 hours later. **F.**, enumeration of young and old D^bNP₃₉₆⁺ CD8⁺T_M in the thymus; $n \geq 3$ individual mice per group for all experiments.

REFERENCES

1. Eberlein J, Davenport B, Nguyen TT, Victorino F, Karimpour-Fard A, Hunter LE, et al. Aging promotes acquisition of naïve-like CD8+ memory T cell traits and enhanced functionalities. *J Clin Invest*. 2016;106(10):3942-60. Epub September 12, 2016 doi: 10.1172/JCI88546.
2. Roberts AD, Ely KH, Woodland DL. Differential contributions of central and effector memory T cells to recall responses. *J Exp Med*. 2005;202(1):123-33. PubMed PMID: 15983064.
3. Hikono H, Kohlmeier JE, Takamura S, Wittmer ST, Roberts AD, Woodland DL. Activation phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells. *J Exp Med*. 2007;204(7):1625-36. PubMed PMID: 17606632.
4. Martin MD, Condotta SA, Harty JT, Badovinac VP. Population dynamics of naive and memory CD8 T cell responses after antigen stimulations in vivo. *J Immunol*. 2012;188(3):1255-65. doi: 10.4049/jimmunol.1101579. PubMed PMID: 22205031; PubMed Central PMCID: PMC3262935.
5. Martin MD, Kim MT, Shan Q, Sompallae R, Xue HH, Harty JT, et al. Phenotypic and Functional Alterations in Circulating Memory CD8 T Cells with Time after Primary Infection. *PLoS Pathog*. 2015;11(10):e1005219. doi: 10.1371/journal.ppat.1005219. PubMed PMID: 26485703; PubMed Central PMCID: PMC4618693.
6. Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? *Nat Rev Immunol*. 2011;11(4):289-95. Epub 2011/03/26. doi: nri2959 [pii] 10.1038/nri2959. PubMed PMID: 21436838.
7. Blackman MA, Woodland DL. The narrowing of the CD8 T cell repertoire in old age. *Curr Opin Immunol*. 2011;23(4):537-42. Epub 2011/06/10. doi: S0952-7915(11)00059-8 [pii] 10.1016/j.coi.2011.05.005. PubMed PMID: 21652194; PubMed Central PMCID: PMC3163762.
8. Chou JP, Effros RB. T cell replicative senescence in human aging. *Current pharmaceutical design*. 2013;19(9):1680-98. PubMed PMID: 23061726; PubMed Central PMCID: PMC3749774.
9. Nikolich-Zugich J. Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. *J Immunol*. 2014;193(6):2622-9. doi: 10.4049/jimmunol.1401174. PubMed PMID: 25193936; PubMed Central PMCID: PMC4157314.
10. Goronzy JJ, Weyand CM. Successful and Maladaptive T Cell Aging. *Immunity*. 2017;46(3):364-78. doi: 10.1016/j.immuni.2017.03.010. PubMed PMID: 28329703.
11. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. *Immunity*. 2010;33(4):451-63. Epub 2010/10/30. doi: S1074-7613(10)00368-7 [pii] 10.1016/j.immuni.2010.10.008. PubMed PMID: 21029957.
12. Walker JM, Slifka MK. Longevity of T-cell memory following acute viral infection. *Adv Exp Med Biol*. 2010;684:96-107. Epub 2010/08/28. PubMed PMID: 20795543.
13. Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. *Science*. 1999;286(5443):1377-81. PubMed PMID: 10558996.
14. Homann D, Teyton L, Oldstone MB. Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. *Nat Med*. 2001;7(8):913-9. PubMed PMID: 11479623.
15. Surh CD, Sprent J. Homeostasis of naive and memory T cells. *Immunity*. 2008;29(6):848-62. Epub 2008/12/23. doi: S1074-7613(08)00506-2 [pii] 10.1016/j.immuni.2008.11.002. PubMed PMID: 19100699.
16. Wojciechowski S, Tripathi P, Bourdeau T, Acero L, Grimes HL, Katz JD, et al. Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. *J Exp Med*. 2007;204(7):1665-75. PubMed PMID: 17591857.

17. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. *Nat Immunol.* 2003;4(3):225-34. PubMed PMID: 12563257.
18. Kurtulus S, Tripathi P, Moreno-Fernandez ME, Sholl A, Katz JD, Grimes HL, et al. Bcl-2 allows effector and memory CD8+ T cells to tolerate higher expression of Bim. *J Immunol.* 2011;186(10):5729-37. Epub 2011/04/01. doi: jimmunol.1100102 [pii] 10.4049/jimmunol.1100102. PubMed PMID: 21451108.
19. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. *Nature reviews Cancer.* 2010;10(8):561-74. doi: 10.1038/nrc2889. PubMed PMID: 20651737.
20. Gentle IE, Moelter I, Lechler N, Bambach S, Vucikujia S, Hacker G, et al. Inhibitor of apoptosis proteins (IAPs) are required for effective T cell expansion/survival during anti-viral immunity in mice. *Blood.* 2013. doi: 10.1182/blood-2013-01-479543. PubMed PMID: 24335231.
21. Grayson JM, Laniewski NG, Lanier JG, Ahmed R. Mitochondrial potential and reactive oxygen intermediates in antigen-specific CD8+ T cells during viral infection. *J Immunol.* 2003;170(9):4745-51. PubMed PMID: 12707355.
22. Salminen A, Ojala J, Kaarniranta K. Apoptosis and aging: increased resistance to apoptosis enhances the aging process. *Cell Mol Life Sci.* 2011;68(6):1021-31. Epub 2010/12/01. doi: 10.1007/s00018-010-0597-y. PubMed PMID: 21116678.
23. Miller RA. Aging and immune function. In: Paul W, editor. *Fundamental Immunology.* 4th ed: Lippincott-Raven Publishers; 1999. p. 947-66.
24. Kim HJ, Nel AE. The role of phase II antioxidant enzymes in protecting memory T cells from spontaneous apoptosis in young and old mice. *J Immunol.* 2005;175(5):2948-59. Epub 2005/08/24. doi: 175/5/2948 [pii]. PubMed PMID: 16116181.
25. Peters T, Weiss JM, Sindrilaru A, Wang H, Oreshkova T, Wlaschek M, et al. Reactive oxygen intermediate-induced pathomechanisms contribute to immunosenescence, chronic inflammation and autoimmunity. *Mech Ageing Dev.* 2009;130(9):564-87. Epub 2009/07/28. doi: S0047-6374(09)00103-1 [pii] 10.1016/j.mad.2009.07.003. PubMed PMID: 19632262.
26. Mak TW, Grusdat M, Duncan GS, Dostert C, Nonnenmacher Y, Cox M, et al. Glutathione Primes T Cell Metabolism for Inflammation. *Immunity.* 2017;46(4):675-89. doi: 10.1016/j.immuni.2017.03.019. PubMed PMID: 28423341.
27. Sahaf B, Heydari K, Herzenberg LA. Lymphocyte surface thiol levels. *Proc Natl Acad Sci U S A.* 2003;100(7):4001-5. PubMed PMID: 12642656.
28. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature.* 2005;435(7042):677-81. PubMed PMID: 15902208.
29. Masopust D, Ha SJ, Vezys V, Ahmed R. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. *J Immunol.* 2006;177(2):831-9. PubMed PMID: 16818737.
30. Song J, So T, Cheng M, Tang X, Croft M. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. *Immunity.* 2005;22(5):621-31. Epub 2005/05/17. doi: S1074-7613(05)00107-X [pii] 10.1016/j.immuni.2005.03.012. PubMed PMID: 15894279.
31. Dunkle A, Dzhalalov I, Gordy C, He YW. Transfer of CD8+ T cell memory using Bcl-2 as a marker. *J Immunol.* 2013;190(3):940-7. doi: 10.4049/jimmunol.1103481. PubMed PMID: 23269245.

32. Choo DK, Murali-Krishna K, Anita R, Ahmed R. Homeostatic turnover of virus-specific memory CD8 T cells occurs stochastically and is independent of CD4 T cell help. *J Immunol.* 2010;185(6):3436-44. doi: 10.4049/jimmunol.1001421. PubMed PMID: 20733203.
33. Kemp RA, Pearson CF, Cornish GH, Seddon BP. Evidence of STAT5-dependent and -independent routes to CD8 memory formation and a preferential role for IL-7 over IL-15 in STAT5 activation. *Immunol Cell Biol.* 2010;88(2):213-9. Epub 2009/12/02. doi: icb200995 [pii] 10.1038/icb.2009.95. PubMed PMID: 19949423; PubMed Central PMCID: PMC2842934.
34. Pandey A, Ozaki K, Baumann H, Levin SD, Puel A, Farr AG, et al. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. *Nat Immunol.* 2000;1(1):59-64. PubMed PMID: 10881176.
35. Willinger T, Freeman T, Hasegawa H, McMichael AJ, Callan MF. Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. *J Immunol.* 2005;175(9):5895-903. Epub 2005/10/21. doi: 175/9/5895 [pii]. PubMed PMID: 16237082.
36. Hand TW, Cui W, Jung YW, Sefik E, Joshi NS, Chandele A, et al. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. *Proc Natl Acad Sci U S A.* 2010;107(38):16601-6. Epub 2010/09/09. doi: 1003457107 [pii] 10.1073/pnas.1003457107. PubMed PMID: 20823247; PubMed Central PMCID: PMC2944719.
37. Zhang X, Fujii H, Kishimoto H, LeRoy E, Surh CD, Sprent J. Aging leads to disturbed homeostasis of memory phenotype CD8(+) cells. *J Exp Med.* 2002;195(3):283-93. Epub 2002/02/06. PubMed PMID: 11828003; PubMed Central PMCID: PMC2193587.
38. Lenz DC, Kurz SK, Lemmens E, Schoenberger SP, Sprent J, Oldstone MB, et al. IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. *Proc Natl Acad Sci U S A.* 2004;101(25):9357-62. PubMed PMID: 15197277.
39. Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, Lefrancois L. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. *Nat Immunol.* 2005;6(8):793-9. PubMed PMID: 16025119.
40. Buck MD, O'Sullivan D, Pearce EL. T cell metabolism drives immunity. *J Exp Med.* 2015;212(9):1345-60. doi: 10.1084/jem.20151159. PubMed PMID: 26261266; PubMed Central PMCID: PMC4548052.
41. Chapman NM, Chi H. mTOR Links Environmental Signals to T Cell Fate Decisions. *Frontiers in immunology.* 2014;5:686. doi: 10.3389/fimmu.2014.00686. PubMed PMID: 25653651; PubMed Central PMCID: PMC4299512.
42. Pollizzi KN, Powell JD. Regulation of T cells by mTOR: the known knowns and the known unknowns. *Trends Immunol.* 2015;36(1):13-20. doi: 10.1016/j.it.2014.11.005. PubMed PMID: 25522665; PubMed Central PMCID: PMC4290883.
43. Phan AT, Doedens AL, Palazon A, Tyrakis PA, Cheung KP, Johnson RS, et al. Constitutive Glycolytic Metabolism Supports CD8+ T Cell Effector Memory Differentiation during Viral Infection. *Immunity.* 2016;45(5):1024-37. doi: 10.1016/j.immuni.2016.10.017. PubMed PMID: 27836431; PubMed Central PMCID: PMC45130099.
44. Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, et al. Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. *Immunity.* 2016;45(2):358-73. doi: 10.1016/j.immuni.2016.07.008. PubMed PMID: 27496729; PubMed Central PMCID: PMC4988919.
45. O'Sullivan D, van der Windt GJ, Huang SC, Curtis JD, Chang CH, Buck MD, et al. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. *Immunity.* 2014;41(1):75-88. doi: 10.1016/j.immuni.2014.06.005. PubMed PMID: 25001241; PubMed Central PMCID: PMC4120664.

46. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. *Cell Metab.* 2014;20(1):61-72. doi: 10.1016/j.cmet.2014.05.004. PubMed PMID: 24930970; PubMed Central PMCID: PMC4079750.
47. Proud CG. Regulation of protein synthesis by insulin. *Biochemical Society transactions.* 2006;34(Pt 2):213-6. doi: 10.1042/BST20060213. PubMed PMID: 16545079.
48. Lochner M, Berod L, Sparwasser T. Fatty acid metabolism in the regulation of T cell function. *Trends Immunol.* 2015;36(2):81-91. doi: 10.1016/j.it.2014.12.005. PubMed PMID: 25592731.
49. Masopust D, Lefrancois L. CD8 T-cell memory: the other half of the story. *Microbes Infect.* 2003;5(3):221-6. PubMed PMID: 12681411.
50. Klonowski KD, Williams KJ, Marzo AL, Blair DA, Lingenheld EG, Lefrancois L. Dynamics of blood-borne CD8 memory T cell migration in vivo. *Immunity.* 2004;20(5):551-62. PubMed PMID: 15142524.
51. Sarkar S, Teichgraber V, Kalia V, Polley A, Masopust D, Harrington LE, et al. Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation. *J Immunol.* 2007;179(10):6704-14. Epub 2007/11/06. doi: 179/10/6704 [pii]. PubMed PMID: 17982060.
52. Kohlmeier JE, Woodland DL. Immunity to respiratory viruses. *Annu Rev Immunol.* 2009;27:61-82. Epub 2008/10/29. doi: 10.1146/annurev.immunol.021908.132625. PubMed PMID: 18954284.
53. Nolz JC, Starbeck-Miller GR, Harty JT. Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions. *Immunotherapy.* 2011;3(10):1223-33. doi: 10.2217/imt.11.100. PubMed PMID: 21995573; PubMed Central PMCID: PMC3214994.
54. Jung YW, Rutishauser RL, Joshi NS, Haberman AM, Kaech SM. Differential localization of effector and memory CD8 T cell subsets in lymphoid organs during acute viral infection. *J Immunol.* 2010;185(9):5315-25. doi: 10.4049/jimmunol.1001948. PubMed PMID: 20921525.
55. Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, et al. Intravascular staining for discrimination of vascular and tissue leukocytes. *Nat Protoc.* 2014;9(1):209-22. doi: 10.1038/nprot.2014.005. PubMed PMID: 24385150; PubMed Central PMCID: PMC4428344.
56. Steinert EM, Schenkel JM, Fraser KA, Beura LK, Manlove LS, Igyarto BZ, et al. Quantifying Memory CD8 T Cells Reveals Regionalization of Immunosurveillance. *Cell.* 2015;161(4):737-49. doi: 10.1016/j.cell.2015.03.031. PubMed PMID: 25957682; PubMed Central PMCID: PMC4426972.
57. Aw D, Hilliard L, Nishikawa Y, Cadman ET, Lawrence RA, Palmer DB. Disorganization of the splenic microanatomy in ageing mice. *Immunology.* 2016;148(1):92-101. doi: 10.1111/imm.12590. PubMed PMID: 26840375; PubMed Central PMCID: PMC4819137.
58. Scimone ML, Felbinger TW, Mazo IB, Stein JV, Von Andrian UH, Weninger W. CXCL12 mediates CCR7-independent homing of central memory cells, but not naive T cells, in peripheral lymph nodes. *J Exp Med.* 2004;199(8):1113-20. PubMed PMID: 15096537.
59. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. *Nat Rev Immunol.* 2003;3(11):867-78. Epub 2003/12/12. doi: 10.1038/nri1222 nri1222 [pii]. PubMed PMID: 14668803.
60. Nolz JC, Harty JT. Protective capacity of memory CD8+ T cells is dictated by antigen exposure history and nature of the infection. *Immunity.* 2011;34(5):781-93. Epub 2011/05/10. doi: S1074-7613(11)00174-9 [pii] 10.1016/j.immuni.2011.03.020. PubMed PMID: 21549619; PubMed Central PMCID: PMC3103642.
61. Van den Broeck W, Derore A, Simoens P. Anatomy and nomenclature of murine lymph nodes: Descriptive study and nomenclatory standardization in BALB/cAnNCrI mice. *J Immunol Methods.* 2006;312(1-2):12-9. Epub 2006/04/21. doi: S0022-1759(06)00064-0 [pii]

10.1016/j.jim.2006.01.022. PubMed PMID: 16624319.

62. Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets, migration patterns, and tissue residence. *Annu Rev Immunol.* 2013;31:137-61. doi: 10.1146/annurev-immunol-032712-095954. PubMed PMID: 23215646.
63. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection generates non-migratory memory CD8⁺ T(RM) cells providing global skin immunity. *Nature.* 2012;483(7388):227-31. doi: 10.1038/nature10851. PubMed PMID: 22388819; PubMed Central PMCID: PMC3437663.
64. Schenkel JM, Masopust D. Tissue-resident memory T cells. *Immunity.* 2014;41(6):886-97. doi: 10.1016/j.immuni.2014.12.007. PubMed PMID: 25526304; PubMed Central PMCID: PMC4276131.
65. Xu RH, Fang M, Klein-Szanto A, Sigal LJ. Memory CD8⁺ T cells are gatekeepers of the lymph node draining the site of viral infection. *Proc Natl Acad Sci U S A.* 2007;104(26):10992-7. PubMed PMID: 17578922.
66. Gasteiger G, Ataide M, Kastenmuller W. Lymph node - an organ for T-cell activation and pathogen defense. *Immunol Rev.* 2016;271(1):200-20. doi: 10.1111/imr.12399. PubMed PMID: 27088916.
67. Chaix J, Nish SA, Lin WH, Rothman NJ, Ding L, Wherry EJ, et al. Cutting edge: CXCR4 is critical for CD8⁺ memory T cell homeostatic self-renewal but not rechallenge self-renewal. *J Immunol.* 2014;193(3):1013-6. doi: 10.4049/jimmunol.1400488. PubMed PMID: 24973450; PubMed Central PMCID: PMC4108510.
68. Di Rosa F, Gebhardt T. Bone Marrow T Cells and the Integrated Functions of Recirculating and Tissue-Resident Memory T Cells. *Frontiers in immunology.* 2016;7:51. doi: 10.3389/fimmu.2016.00051. PubMed PMID: 26909081; PubMed Central PMCID: PMC4754413.
69. Kimura MY, Pobeziński LA, Guintier TI, Thomas J, Adams A, Park JH, et al. IL-7 signaling must be intermittent, not continuous, during CD8⁺ T cell homeostasis to promote cell survival instead of cell death. *Nat Immunol.* 2013;14(2):143-51. doi: 10.1038/ni.2494. PubMed PMID: 23242416; PubMed Central PMCID: PMC3552087.
70. Westera L, van Hoeven V, Drylewicz J, Spierenburg G, van Velzen JF, de Boer RJ, et al. Lymphocyte maintenance during healthy aging requires no substantial alterations in cellular turnover. *Aging cell.* 2015. doi: 10.1111/ace.12311. PubMed PMID: 25627171.
71. Marzo AL, Yagita H, Lefrançois L. Cutting edge: migration to nonlymphoid tissues results in functional conversion of central to effector memory CD8⁺ T cells. *J Immunol.* 2007;179(1):36-40. PubMed PMID: 17579018; PubMed Central PMCID: PMC2861291.
72. Kohlmeier JE, Miller SC, Woodland DL. Cutting edge: Antigen is not required for the activation and maintenance of virus-specific memory CD8⁺ T cells in the lung airways. *J Immunol.* 2007;178(8):4721-5. PubMed PMID: 17404250.
73. Thome JJC, Yudanin N, Ohmura Y, Kubota M, Grinshpun B, Sathaliyawala T, et al. Spatial Map of Human T Cell Compartmentalization and Maintenance over Decades of Life. *Cell.* 2014;159:814-28.
74. Best JA, Blair DA, Knell J, Yang E, Mayya V, Doedens A, et al. Transcriptional insights into the CD8⁺ T cell response to infection and memory T cell formation. *Nat Immunol.* 2013;14(4):404-12. doi: 10.1038/ni.2536. PubMed PMID: 23396170; PubMed Central PMCID: PMC3689652.
75. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, et al. Hypoxia-inducible factors enhance the effector responses of CD8⁺ T cells to persistent antigen. *Nat Immunol.* 2013;14(11):1173-82. doi: 10.1038/ni.2714. PubMed PMID: 24076634; PubMed Central PMCID: PMC3977965.
76. Dominguez CX, Amezcua RA, Guan T, Marshall HD, Joshi NS, Kleinstein SH, et al. The transcription factors ZEB2 and T-bet cooperate to program cytotoxic T cell terminal differentiation in response to LCMV viral infection. *J Exp Med.* 2015;212(12):2041-56. doi: 10.1084/jem.20150186. PubMed PMID: 26503446; PubMed Central PMCID: PMC4647261.

77. Gray SM, Kaech SM, Staron MM. The interface between transcriptional and epigenetic control of effector and memory CD8(+) T-cell differentiation. *Immunol Rev.* 2014;261(1):157-68. doi: 10.1111/imr.12205. PubMed PMID: 25123283.
78. Gelderman KA, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. *Proc Natl Acad Sci U S A.* 2006;103(34):12831-6. PubMed PMID: 16908843.
79. Hildeman DA, Mitchell T, Teague TK, Henson P, Day BJ, Kappler J, et al. Reactive oxygen species regulate activation-induced T cell apoptosis. *Immunity.* 1999;10(6):735-44. PubMed PMID: 10403648.
80. Eberlein J, Nguyen TT, Victorino F, Golden-Mason L, Rosen HR, Homann D. Comprehensive assessment of chemokine expression profiles by flow cytometry. *J Clin Invest.* 2010;120(3):907-23. Epub 2010/03/04. doi: 40645 [pii] 10.1172/JCI40645. PubMed PMID: 20197626; PubMed Central PMCID: PMC2827956.
81. Amir el AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. *Nat Biotechnol.* 2013;31(6):545-52. doi: 10.1038/nbt.2594. PubMed PMID: 23685480; PubMed Central PMCID: PMC4076922.
82. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005;102(43):15545-50. Epub 2005/10/04. doi: 0506580102 [pii] 10.1073/pnas.0506580102. PubMed PMID: 16199517; PubMed Central PMCID: PMC1239896.

INDEX OF FIGURES, SUPPLEMENTARY FIGURES AND SUPPLEMENTARY TABLES

I. FIGURES 1-7

- 1: Temporal regulation of major survival-associated components by aging CD8⁺T_M.
- 2: Life & death of aging CD8⁺T_M.
- 3: CD127/CD122 expression, signaling and homeostatic proliferation of aging CD8⁺T_M.
- 4: Metabolic adaptations of aging CD8⁺T_M.
- 5: Increasing abundance and accelerated maturation of aging CD8⁺T_M in the splenic WP.
- 6: Progressive accumulation of aging CD8⁺T_M in peripheral LNs.
- 7: Redistribution of aging CD8⁺T_M from NLTs to lymphoid tissues.

II. SUPPLEMENTARY FIGURES S1-S5

- S1: Temporal regulation of survival- and apoptosis-related gene expression by p14 T_{E/M}.
- S2: Homeostasis of aging CD8⁺T_M: staining controls, cell cycle GSEA, and cytokine mRNA levels.
- S3: Metabolic adaptations of aging CD8⁺T_M.
- S4: Phenotypic properties of RP and WP CD8⁺T_M populations in young and old mice.
- S5: Chemokine receptor-dependent and CD62L-independent trafficking of young and old p14 T_M.

III. SUPPLEMENTARY TABLE S1

- S1: Reagents & Materials

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure S1




Figure S1. Temporal regulation of survival- and apoptosis-related gene expression by p14 $T_{E/M}$. Transcriptional analyses were conducted with p14 T_E (day 8) and T_M (d46, d156, d286 and d400) purified from LCMV-challenged p14 chimeras and processed directly *ex vivo* for microarray hybridization as detailed in ref.¹. The panels depict specific mRNA expression patterns of p14 $T_{E/M}$ as a function of time after LCMV challenge, and the vertical gray bars indicate the transition period from T_E stage (d8) to early T_M stage (d42). **A.**, Bcl-2 family group IA (anti-apoptotic); **B.**, Bcl-2 family group IB (pro-apoptotic); **C.**, Bcl-2 family group IC (BH3-like contenders); **D.**, inhibitor of apoptosis proteins (IAPs, involved in the regulation of caspases, apoptosis, inflammatory signaling and immunity); **E.**, caspases. The data shown here for *Bcl2*, *Bcl2l1* (*Bcl-x_L*), *Bcl2l11* (*BIM*) and *Casp3* are also displayed in **Fig.1C/D**. All data are SEM with $n \geq 3$ individual mice/time point and asterisks indicate statistical significance comparing young (d40) and older ($\geq d156$) p14 T_M using one-way ANOVA with Dunnett's multiple comparisons test unless noted otherwise (*, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; (*), significance of differential *Bcl2l11* expression comparing d46 and d400 by Student's t-test but not ANOVA). For easier identification, significant differences emerging over the course of the memory phase are highlighted in red (up-regulation) or green (down-regulation).

Figure S2




Figure S2. Homeostasis of aging CD8⁺T_M; staining controls, cell cycle GSEA, and cytokine mRNA levels. **A.**, left: control stains (black tracing: pSTAT5, gray histograms: mlgG₁ isotype) documenting differential constitutive pSTAT5 levels in DP vs. DN thymocytes in agreement with Van De Wiele *et al.*, J. Immunol. 172: 4235-4244, and thus absence of elevated non-specific staining using the pSTAT5 clone 47 antibody; right: *ex vivo* pSTAT5 stains of splenic CD8⁺T_M (d203); the blocking control (gray histogram) was performed by pre-incubation of the pSTAT5 antibody with an excess of pY694 peptide. **B.**, GSEAs were conducted for aging p14 T_M as detailed in Methods and demonstrate a non-significant negative enrichment for the cell cycle-associated KEGG gene set (NES = -0.68). **C.**, RNA was extracted from total spleen, MLN and BM cells obtained from young (d49) and old (d666) LCMV-immune p14 chimeras and analyzed by qRT-PCR as detailed in Methods; asterisks indicate significantly different IL7 or IL15 expression levels in respective young vs. old tissues (data from 1 of 2 similar experiments). All data are SEM with n≥3 individual mice.

Figure S3




Figure S3. Metabolic adaptations of aging CD8⁺T_M. **A.**, temporal regulation of *Insr* expression (p14 T_{E/M} microarray data). **B.**, summary of GSEAs that identify temporally regulated p14 T_M-expressed gene sets within the KEGG category of “genetic information processing” (GIP; no other pathways in the GIP module demonstrated progressive temporal enrichment or depletion). **C.-E.**, CD8⁺T cell survival under conditions of lipogenesis or lipolysis inhibition. Spleen cells from naïve and indicated LCMV-infected B6 mice were cultured under conditions of “withdrawal apoptosis” in the presence of titrated amounts of indicated inhibitors or vehicle, and the survival of defined subsets (CD44^{lo}CD8⁺T_N [dark gray], D^bNP₃₉₆⁺ and D^bGP₃₃⁺ CD8⁺T_E [white] as well as young [light gray] and aged [black] D^bNP₃₉₆⁺ and D^bGP₃₃⁺ CD8⁺T_M) was quantified 24h later as detailed in Methods; given the differential survival of the different CD8⁺T cell populations in the absence of inhibitor, their relative survival under this condition was set for comparative purposes at 100%. All data are displayed as inhibitor titration curves (left) and under select conditions of inhibitor concentration (right). **C.**, fatty acid synthase (FASN) inhibitor C75. **D.**, adipose triglyceride lipase (ATGL) inhibitor atglitastin. **E.**, inhibition of lysosomal acidification by chloroquine (n=4 mice/group; representative data from one of two experiments). **F.**, JC-1 stains of young and aged D^bNP₃₉₆⁺ CD8⁺T_M. JC-1 is a membrane-permeant dye that exhibits potential-dependent accumulation in mitochondria as indicated by a green (~529nm) to red (~590) fluorescence shift; accordingly, mitochondrial depolarization decreases the red/green fluorescence intensity (incubation with FCCP prior to JC-1 stains was used as a control to dissipate the electrochemical proton gradient). **G.**, temporal regulation of *Ppargc1a* expression (p14 T_{E/M} microarray data). **H.**, PGC-1α (*Ppargc1a* gene product) expression by young and old LCMV-specific CD8⁺T_M (n=4 mice/group).

Figure S4




Figure S4. Phenotypic properties of RP and WP CD8⁺T_M populations in young and old mice. **A.**, intravascular CD8 staining labels blood-borne CD8⁺T cells, a very small fraction of LN cells (InLN: inguinal LN), and permits the distinction of splenic RP and WP cells (*cf.* refs.^{55,56}). **B.**, relative fraction of young and old D^bGP₃₃⁺ CD8⁺T_M located in the splenic WP. **C.**, viSNE rendering of the D^bGP₃₃⁺ CD8⁺T_M phenotype space in RP vs. WP of young (top) and old (bottom) LCMV-immune mice. **D.**, individual phenotypic characteristics of D^bGP₃₃⁺ CD8⁺T_M RP and WP populations in young (left) and old (right) mice. **E.**, direct comparison of young and old D^bNP₃₉₆⁺ (left) and D^bGP₃₃⁺ (right) CD8⁺T_M in RP (top) and WP (bottom); n≥3 mice/time point.

Figure S5




Figure S5. Chemokine receptor-dependent and CD62L-independent trafficking of young and old p14 T_M. **A.**, left: histograms are gated on blood-borne p14 T_M from young (d40, gray filled histograms) and old (d655, black tracings) LCMV-immune p14 chimeras; the asterisks indicate significant CCR7 and intracellular CXCR4 expression differences (n=3-5 mice). Right: experimental flow chart for p14 T_M trafficking experiments. Splenic p14 T_M populations obtained from young (d49) and old (d664) p14 chimeras were differentially labeled with CFSE, combined at a ratio of 1:1, and cultured for 1h at 37°C in the absence (control/ctrl) or presence of 25ng/ml pertussis toxin (Ptx) as described in Methods. Mixtures containing 4.2x10⁵ young and old p14 T_M each were subsequently transferred i.v. into B6 recipients and retrieved from various tissues 42h later. **B.**, enumeration of young (top) and old (bottom) p14 T_M in spleen and lymph nodes; the values indicate the factor by which Ptx treatment reduced respective p14 T_M trafficking to indicated LNs (n=4 recipients each of mixed ctrl- or Ptx-treated p14 T_M populations). **C.**, aged p14 T_M (d630) were transferred into B6 recipients treated with rlgG2a isotype or αCD62L antibody, and retrieved 48h later as detailed in **Fig. 7A**. Note the enhanced accumulation of aged p14 T_M in spleen and BM under conditions of CD62L blockade, likely constituting a compensatory increase due to p14 T_M exclusion from LNs (n=4 mice/group).

Table S1. Reagents & Materials					
Name or antigen	Other name(s)	Antibody	Ab species/isotype	Format	Source
Various T cell, leukocyte & congenic markers					
CD3e		145-2C11	hamster IgG	FITC/PE/PerCP/eF450	BDBiosciences/ebioscience
CD4		RM4-5	rlgG2a	FITC/PE/PerCP/APC	BDBiosciences/ebioscience
CD8a		53-6.7	rlgG2a	FITC/PE/PerCP/APC/ PE-Cy7/APC-Cy7/ PerCP-Cy5.5/BV421	BDBiosciences/ebioscience BDBiosciences/Biolegend
CD44		IM7	rlgG2b	FITC/PE/APC	BDBiosciences/ebioscience
CD45		30-F11	rlgG2b	FITC	Biolegend
CD45.1		A20	mlgG2a	biotin/FITC/PE/APC	BDBiosciences
CD45.2		104	mlgG2a	FITC/PE/APC	ebioscience
CD62L	L-selectin	MEL-14	rlgG2a	FITC/PE/APC/APC-Cy7	ebioscience
CD90.1		OX-7	mlgG1	FITC/PerCP	BDBiosciences
		HIS51	mlgG2a	FITC/PE/APC	BDBiosciences/ebioscience
CD90.2		53-2.1	rlgG2a	FITC/PE/APC	BDBiosciences
Cytokine, chemokine & other receptors					
CD27	TNFRSF7	LG.7F9	hamster IgG	PE-Cy7	ebioscience
CD43		S7	rlgG2a	FITC	BDBiosciences
CD62L	L-selectin	MEL-14	rlgG2a	PE/APC/APC-efluor780	ebioscience
CD122	IL-2Rb	5H4	rlgG2a	PE	ebioscience
CD127	IL-7Ra	A7R34	rlgG2a	FITC/PE/BV711	ebioscience/Biolegend
		SB/14	rlgG2a	PE	BDBiosciences
CCR7	CD197	4B12	rlgG2a	PE	ebioscience/Biolegend
CXCR3	CD183	CXCR3-173	hamster IgG	BV510	Biolegend
CXCR4	CD184	2B11	rlgG2b	PE	BDBiosciences
CX3CR1		SA011F11	mlgG2a	BV605	Biolegend
KLRG1		2F1	hamster IgG	PerCP-efluor710	ebioscience
INSR	CD220	polyclonal (FAB1544P)	goat IgG	PE	RnD Systems
Intracellular antigens					
IFN γ		XMG1.2	rlgG1	PE/APC/PE-Cy7	BDBiosciences/ebioscience
Bcl-2		3F11	hamster IgG	PE	BDBiosciences
Bcl-xL		7B2.5	mlgG3	PE	Southern Biotech
BIM		Ham151-149	hamster IgG	PE	P. Marrack
Caspase-3 (active)		C92-605	rabbit	PE	BDBiosciences
pSTAT5 (Y694)		47	mlgG1	Alx647	BDBiosciences
		polyclonal (9351)	rabbit	affinity-purified	Cell Signaling Technology
pSTAT5 (Y694/699) blocking peptide		n/a (sc-11761P)	n/a	n/a	Santa Cruz Biotechnology
pS6 ribosomal protein (S235/236)		REA454	IgG1	PE	Miltenyi Biotec
mTOR		7C10	rabbit IgG	PE	Cell Signaling Technology
Ki67		B56	mlgG1	FITC	BDBiosciences
BrdU (bromodeoxyuridine)		B44	mlgG1	FITC	BDBiosciences
Glut1		EPR3915	rabbit IgG	purified/PE	Abcam
Glut3		polyclonal (ab41525)	rabbit IgG	purified	Abcam
PGC-1a		polyclonal (sc-130670)	rabbit IgG	purified	Santa Cruz Biotechnology
Isotype controls & "second step" reagents					Abcam
KLH		11711	mlgG1	PE	RnD Systems
unknown			mlgG1	PE	Invitrogen/Caltag
unknown		MOPC-21	mlgG1	FITC	BDBiosciences
Dansyl		27-35	mlgG2b	PE/APC	BDBiosciences
unknown		R3-34	rlgG1	PE/APC	BDBiosciences
unknown		R35-95	rlgG2a	FITC/PE	BDBiosciences
unknown		A95-1	rlgG2b	FITC/PE	BDBiosciences
TNP		A19-3	hamster IgG	purified/PE	BDBiosciences
unknown		G235-2356	hamster IgG	PE	BDBiosciences
anti-hamster		G70-204/G94-90.5	mlgG1	PE	BDBiosciences
anti-rabbit			donkey F(ab') ₂	FITC/Cy5	Jackson Immunoresearch
anti-rabbit		polyclonal (A11034)	goat IgG	Alx488	Life Technologies
anti-human Fc			donkey F(ab') ₂	PE	Jackson Immunoresearch
anti-mlgG2a/b Zenon kits (for mab pre-conjugation)			F(ab') ₂	Alx647	Invitrogen/Molecular Probes
Streptavidin	SAv	n/a	n/a	FITC/PE/APC/PB/BV421	Invitrogen/Molecular Probes
In vivo treatment					
CD62L		MEL-14	rlgG2a	purified	Biolegend
KLH (isotype control)		RTK2758	rlgG2a	purified	Biolegend
CD8b (intravascular staining)		53-5.8	rlgG1	PE	Biolegend

Magnetic bead-conjugated antibodies				
EasySep mouse CD8+ T cell enrichment kit	n/a/(19753)			StemCell Technologies
StemSep mouse CD8+ T cell enrichment kit	n/a (13053)			StemCell Technologies
EasySep mouse PE positive selection kit	n/a (18554)			StemCell Technologies
CD45R (B220) MicroBeads	n/a (130-049-501)			Miltenyi Biotec
CD4 (L3T4) MicroBeads (#130-049-201)				Miltenyi Biotec
Anti-PE MicroBeads (#130-048-801)				Miltenyi Biotec
Dynabeads mouse pan B (B220) (#11441D)				Invitrogen/Dynal
MHC-I monomers & tetramers				
DbNP396	n/a	n/a	biotin (PE, APC, BV421)	NIH Tetramer Core Facility
DbGP33	n/a	n/a	biotin (PE, APC, BV421)	NIH Tetramer Core Facility
Dyes, probes & compounds				
CFDA-SE (CFSE)	n/a (C1157)	n/a		Invitrogen/Molecular Probes
Annexin V	n/a	n/a	PE/APC/PB	Invitrogen/Molecular Probes/ BDBiosciences
PI	propidium iodide	n/a (P1304MP)		Invitrogen/Molecular Probes
7AAD	7-aminoactinomycin D	n/a (00-6993-50)		Invitrogen/Molecular Probes
YO-PRO-1		n/a (Y3603)		Invitrogen/Molecular Probes
Zombie dye		n/a (423112/423114)	n/a	green/violet
Glut1.RBD.GFP		n/a (NC1190645)	n/a	GFP
DiOC6(3) 3,3'-dihexyloxacarbocyanine iodide	n/a (D273)	n/a		Invitrogen/Molecular Probes
Mito Tracker Green (MTG)		n/a (M7514)		ThermoFisher
Tetramethylrhodamine (TMRE)		n/a (T669)		ThermoFisher
JC-1 Assay Kit		n/a (M34152)		ThermoFisher
HE	dihydroethidium	n/a (D1168)		Invitrogen/Molecular Probes
ALM-Alx488 (C5 maleimide [thiol-reactive probe])	n/a (A10254)	n/a	Alx488	Invitrogen/Molecular Probes
ThiolTracker Violet (glutathione detection reagent) (T10096)		n/a		Invitrogen/Molecular Probes
2-NBDG (glucose uptake cell-based assay kit)	n/a (600470)	n/a		Cayman Chemical
Bodipy 493/503		n/a (D3922)		ThermoFisher
Bodipy FL C16		n/a (D3281)		ThermoFisher
Bodipy LDL		n/a (L3483)		ThermoFisher
C75 (FASN inhibitor)		n/a (10005270)		Cayman Chemical
Atglistatin (ATGL/PNPLA2 inhibitor)		n/a (15284)		Cayman Chemical
Chloroquine (lysosomal acidification inhibitor)		n/a (C6628)		Sigma
Recombinant cytokines				
mIL-7	n/a (217-17)	n/a	recombinant, purified	Peptotech
mIL-15	n/a (210-15)	n/a	recombinant, purified	Peptotech
n/a: not applicable; m: mouse, r: rat, h: human				